<SEC-DOCUMENT>0001213900-23-065005.txt : 20230809 <SEC-HEADER>0001213900-23-065005.hdr.sgml : 20230809 <ACCEPTANCE-DATETIME>20230809160121 ACCESSION NUMBER: 0001213900-23-065005 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 30 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Raphael Pharmaceutical Inc. CENTRAL INDEX KEY: 0001415397 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 260204284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53002 FILM NUMBER: 231154977 BUSINESS ADDRESS: STREET 1: SUITE 105 - 5348 VEGAS DR. CITY: LAS VEGAS STATE: NV ZIP: 89108 BUSINESS PHONE: 702-442-1166 MAIL ADDRESS: STREET 1: SUITE 105 - 5348 VEGAS DR. CITY: LAS VEGAS STATE: NV ZIP: 89108 FORMER COMPANY: FORMER CONFORMED NAME: Easy Energy Inc DATE OF NAME CHANGE: 20071017 </SEC-HEADER> <DOCUMENT> <TYPE>10-Q <SEQUENCE>1 <FILENAME>f10q0623_raphaelpharma.htm <DESCRIPTION>QUARTERLY REPORT <TEXT> <XBRL> <?xml version="1.0" encoding="ASCII"?> <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --> <!-- Created: Tue Aug 08 05:06:14 UTC 2023 --> <html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:raph="http://www.raphaelpharmaceutical.com/20230630" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml"> <head> <title> </title> <meta content="text/html" http-equiv="Content-Type" /> </head> <body><div style="font: 10pt Times New Roman, Times, Serif"><div> </div><p style="margin: 0"></p><div> </div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"> </div></div><!-- Field: /Rule-Page --><div> </div><p style="margin: 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Mark One)</b> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">☒</ix:nonNumeric> <b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the quarterly period ended: <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">June 30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></ix:nonNumeric></b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">☐</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from              to            </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">000-53002</ix:nonNumeric></b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>Raphael Pharmaceutical Inc.</b></ix:nonNumeric></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center"> </td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26-0204284</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of</span></td> <td style="text-align: center"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</span></td> <td style="text-align: center"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1"><b>4 Lui Paster Street</b></ix:nonNumeric></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Tel Aviv-Jaffa</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">6803605</ix:nonNumeric></b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(+972)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">52-775-5072</ix:nonNumeric></b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant’s telephone number, including area code)</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act: </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> ☒ No ☐</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> ☒ No ☐</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☒</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☒</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</span></ix:nonNumeric></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">☒</ix:nonNumeric></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of August 9, 2023: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">16,368,168</ix:nonFraction>.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"> </div></div><!-- Field: /Rule-Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div> </div><!-- Field: Page; Sequence: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 8%"> </td> <td style="width: 82%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Financial Statements</a></span></td> <td> </td> <td style="text-align: center">F-1</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td> <td> </td> <td style="text-align: center">1</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Quantitative and Qualitative Disclosures About Market Risk</a></span></td> <td> </td> <td style="text-align: center">6</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Controls and Procedures</a></span></td> <td> </td> <td style="text-align: center">6</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Legal Proceedings</a></span></td> <td> </td> <td style="text-align: center">7</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Risk Factors</a></span></td> <td> </td> <td style="text-align: center">7</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Exhibits</a></span></td> <td> </td> <td style="text-align: center">7</td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div> </div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p><div> </div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. Financial Statements</b> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RAPHAEL PHARMACEUTICAL INC. AND ITS SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF JUNE 30, 2023</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>  </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Interim Balance Sheets <span style="text-decoration:underline">(PCAOB ID No. 6629)</span></b></span></a></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2</b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 90%; text-align: justify"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Interim Statements of Comprehensive Loss</b></span></a></td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-3</b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity</b></span></a></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4</b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Interim Statements of Cash Flows</b></span></a></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-5</b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Interim Financial Statements</b></span></a></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6 – F-8</b></span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>  </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - -</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><div> </div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>(Unaudited)</b></span></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Audited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Current assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">111</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">288</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Total current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">331</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Fixed assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">119</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">333</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Liabilities and stockholders’ equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Other account payables and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">141</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">224</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Payable to related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Total current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Stockholders’ equity (deficit):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0.125in">Common stock, $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction></ix:nonFraction> par value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0pt; padding-left: 0.25in">Authorized: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">21,020,560</ix:nonFraction></ix:nonFraction> shares at June 30, 2023 and December 31, 2022;</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Issued and outstanding: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">16,368,168</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">15,624,040</ix:nonFraction></ix:nonFraction> at June 30, 2023 and December 31, 2022, respectively;</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">164</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">157</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Additional paid-in capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">6,482</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">5,975</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">6,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">6,026</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Total stockholders’ equity (deficit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">61</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0pt; padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total liabilities and stockholders’ equity (deficit)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">119</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">333</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of the condensed consolidated interim financial statements.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Page; Sequence: 4; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 0pt">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">407</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">170</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">293</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">84</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">617</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Operating loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">677</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">787</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">419</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Total financial expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">681</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">812</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">417</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">627</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt"><div style="-sec-ix-hidden: hidden-fact-3; -sec-ix-hidden: hidden-fact-2; -sec-ix-hidden: hidden-fact-1; -sec-ix-hidden: hidden-fact-0">Basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.06</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.03</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.05</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-bottom: 4pt; padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-7; -sec-ix-hidden: hidden-fact-6; -sec-ix-hidden: hidden-fact-5; -sec-ix-hidden: hidden-fact-4">Weighted average number of shares of common stock used in computing basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">16,037,214</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">13,342,679</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">16,109,514</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">13,647,151</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of the condensed consolidated interim financial statements.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div> </div><!-- Field: Page; Sequence: 5; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<br/> paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>equity</b></span></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">15,624,040</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">157</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">5,975</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">6,026</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">106</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of common stock and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">378,750</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">146</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">149</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Balance as of March 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,002,790</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">160</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,121</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">6,290</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Issuance of common stock and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">164,378</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">163</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">165</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock in exchange for services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">201,000</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">198</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">417</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">417</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Balance as of June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,368,168</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">164</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,482</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">6,707</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">61</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<br/> paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of January 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">12,970,540</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">130</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,665</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">2,667</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">128</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of common stock and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">320,000</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">157</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">161</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Balance as of March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">13,290,540</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">133</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,822</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">2,852</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">103</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Issuance of common stock and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">655,000</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">345</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">352</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of common stock in exchange for services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">280,000</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">287</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">290</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Balance as of June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">14,225,540</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">143</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">3,454</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">3,479</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of the condensed consolidated interim financial statements.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Page; Sequence: 6; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Cash flows from operating activities</span></td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">681</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">812</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment in exchange for services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">290</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd">36</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd">258</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Account payables and related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" sign="-" unitRef="usd">170</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" sign="-" unitRef="usd">66</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd">314</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd">312</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Advance payment on account of shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="raph:AdvancePaymentOnAccountOfShares" scale="3" unitRef="usd">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">312</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Change in cash and cash equivalents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">177</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">18</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents at the beginning of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents at the end of the period</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">111</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">135</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">less than 1 thousand.</td> </tr></table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the condensed consolidated interim financial statements.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div> </div><!-- Field: Page; Sequence: 7; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><div> </div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b> </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b> </b></p><div> </div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE</b></span> <b>1:-</b></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> GENERAL</b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Raphael Pharmaceutical Inc. (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold <ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="raph:IssuedAndOutstandingShareCapitalPercentage" scale="-2" unitRef="pure">90</ix:nonFraction>% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining <ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="raph:CommonStockPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the issued and outstanding common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">100</ix:nonFraction></ix:nonFraction>) shares of the Company’s issued and outstanding common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, Raphael and the Company completed the Share Exchange pursuant to which <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares">9,459,253</ix:nonFraction> shares of common stock were issued to the shareholders of Raphael so that they became the holders of <ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="raph:IssuedAndOutstandingShareCapitalPercentage" scale="-2" unitRef="pure">90</ix:nonFraction>% of the issued and outstanding shares of common stock of the Company immediately after the Share Exchange while the Company’s shareholders held, following the Share Exchange, <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,051,028</ix:nonFraction> shares of common stock which represents <ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="raph:CommonStockPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company’s common stock began public trading on the over-the-counter market in the U.S. in January 2023 under the symbol “RAPH”.</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going concern and management plans</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of June 30, 2023, the Company’s accumulated deficit was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsUnappropriated" scale="3" unitRef="usd">6,706</ix:nonFraction>. The Company has funded its operations to date primarily through equity financing and the issuance of a loan.  Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p></ix:nonNumeric><div> </div><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div> </div><!-- Field: Page; Sequence: 8; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b> </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b> </b></p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL (Cont.)</b></span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</p></ix:continuation><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><div> </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> NOTE 2:- </b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2022. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2022, are applied consistently in these interim financial statements.</p></ix:nonNumeric><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><div> </div><ix:nonNumeric contextRef="c0" escape="true" name="srt:CondensedFinancialStatementsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED INTERIM FINANCIAL STATEMENTS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Operating results for the six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</p></ix:nonNumeric><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"></p><div> </div><!-- Field: Page; Sequence: 9; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b> </b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share and per share data)</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 142.9pt; text-align: justify"> </p><div> </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHAREHOLDERS’ EQUITY </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company issued <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">255,750</ix:nonFraction> shares of common stock following certain share purchase agreements dated November and December 2022.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2022, the Company signed an agreement to raise $<ix:nonFraction contextRef="c47" decimals="1" format="ixt:num-dot-decimal" name="raph:CompanyRaisedPricePerShare" scale="0" unitRef="usdPershares">7.5</ix:nonFraction> and to issue <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">6,000</ix:nonFraction> shares of common stock and <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="raph:PurchaseWarrants" scale="0" unitRef="shares">18,000</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">1.25</ix:nonFraction> per share to certain investor of the Company. The warrants are exercisable until February 28, 2024. The investment above and share issuance took place in January 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2023, certain investor of the Company and the Company signed an agreement to raise $<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="raph:CompanyRaisedAmount" scale="3" unitRef="usd">250</ix:nonFraction> and to issue <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">250,000</ix:nonFraction> shares of common stock and <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="raph:PurchaseWarrants" scale="0" unitRef="shares">100,000</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">1.13</ix:nonFraction> per share following the exercise of an option for additional investment. The warrants are exercisable until April 30, 2024. In January 2023, the investor and the Company agreed on $<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="3" unitRef="usd">117</ix:nonFraction> out of the $<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="3" unitRef="usd">250</ix:nonFraction> investment. As a result, the Company received $<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherValueOutstanding" scale="3" unitRef="usd">117</ix:nonFraction> and issued <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">117,000</ix:nonFraction> shares of common stock and the issuance of <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="raph:PurchaseWarrants" scale="0" unitRef="shares">100,000</ix:nonFraction> warrants to purchase common stock of the Company were cancelled.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From March through June, 2023, certain investors of the Company and the Company signed an agreement to raise $<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="raph:CompanyRaisedAmount" scale="3" unitRef="usd">190</ix:nonFraction> and to issue <ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">164,378</ix:nonFraction> shares of common stock. The shares were issued in April 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2023, certain investor of the Company and the Company signed an agreement to exercise investors warrants into Company’s common stock. In May 2023, the investor transferred $<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TransferToInvestments" scale="3" unitRef="usd">123</ix:nonFraction>. As of June 30, 2023 the stock weren’t issued yet and as such, investors’ funds were recorded as an advance on account of shares.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, the Company issued <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">201,000</ix:nonFraction> shares of common stock to Way of Life Cannabis Ltd., or Wolc, in connection with the services agreement dated October 2020. The value of the shares issued was based on the value of the service provided and amounted to $<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd">200</ix:nonFraction>.</span></td></tr> </table></ix:nonNumeric><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div> </div><!-- Field: Page; Sequence: 10; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p><div> </div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.</i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>On May 14, 2021, Raphael Pharmaceutical Ltd., an Israeli company, and Easy Energy, Inc., a Nevada corporation, completed a share exchange agreement, or the Share Exchange, pursuant to which the shareholders of Raphael Pharmaceutical Ltd. became the holders of 90% of the issued and outstanding share capital of Easy Energy, Inc., while Easy Energy, Inc.’s shareholders hold, following the share exchange, 10% of Easy Energy, Inc. On May 19, 2021, as agreed by the parties to the Share Exchange, Easy Energy, Inc. changed its name to Raphael Pharmaceutical Inc. Unless otherwise mentioned or unless the context requires otherwise, when used in this prospectus, the terms “Raphael,” “Company,” “we,” “us,” and “our” refer to Raphael Pharmaceutical Inc. and its subsidiary, Raphael Pharmaceutical Ltd., or Raphael Israel. References to Easy Energy are to Easy Energy, Inc. Unless otherwise mentioned or unless the context requires otherwise, the information provided in this Quarterly Report on Form 10-Q relates to Raphael Israel.</i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory pathways that we may elect to utilize in seeking U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and other regulatory approvals, if any;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to our product candidates;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential cost of our rheumatoid arthritis product candidate, or RA and RA product candidate, respectively, for patients;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the timing of commencing clinical trials;</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the supply of the active pharmaceutical ingredient for our product candidates;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payor reimbursement for our product candidates;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding anticipated expenses, capital requirements and our needs for additional financing;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion and receiving favorable results of clinical trials for our product candidates; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the filing by us, and the subsequent issuance of patents to us, by the U.S. Patent and Trademark Office and other governmental patent agencies.</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and investing in our common stock, you should carefully review the risks and uncertainties described in this Quarterly Report on Form 10-Q, and those described from time to time in our future reports filed with the Securities and Exchange Commission. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div> </div><!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on full spectrum cannabis oil or purified cannabinoids, or CBD. Unless indicated otherwise, we plan on using oil derived from CBD strains with low levels of Tetrahydrocannabinol, or THC. All references to the use of CBD in our product candidates refer to CBD strains with less than 0.3% of THC.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently in the pre-clinical development stage for our lead product candidate, our Rheumatoid Arthritis (RA) product candidate for the treatment of RA. In addition, we are aiming to develop a pharmaceutical drug product for the treatment of hyperinflammatory syndrome and lung inflammation related to COVID-19. At Rambam Health Care Campus, or Rambam Hospital, we have successfully completed preclinical studies on human-derived immune cells and mouse models for both the COVID-19 and RA products.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 9, 2022, we filed an application for a clinical trial with the Medical Cannabis Unit of the Ministry of Health of Israel, or MOH. On February 16, 2022 we submitted an application with the Helsinki Committee at Rambam Hospital for a clinical trial in COVID-19 patients. On March 27, 2023, the Israel Ministry of Health, or MOH, accepted our proposal for a clinical trial aimed at preventing the deterioration of hospitalized COVID-19 patients. We will commence the clinical trial during 2023. We plan to submit a human trial application in 2023 to conduct a proof-of-concept experiment for our RA product.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the data obtained from our pre-clinical studies at Rambam Hospital, we are currently in the process of developing a revolutionary and patentable formula designed to treat inflammation. These studies have provided promising results, revealing a remarkable synergistic anti-inflammatory effect of the formula on immune cells sourced from donors, as well as in mice models for lung inflammation and rheumatoid arthritis (RA).</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we move forward, our focus will be on further investigating and refining the formula through continued pre-clinical research. Our ultimate goal is to ensure that the formula meets all the necessary standards and regulations set forth by the FDA, allowing us to progress towards clinical treatments.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our vision is to emerge as a pioneering company at the forefront of formulating pharmaceutical drugs that harness the potential of purified cannabinoids and full-spectrum CBD oil. Our primary mission is to cater to the unmet medical requirements of patients grappling with various disorders, with a particular focus on conditions linked to inflammation, such as chronic lung inflammation, RA and COVID-19.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By leveraging our expertise in this field, we are committed to providing innovative solutions to improve the lives of those afflicted with these challenging medical conditions. Through our dedication to research, development, and compassionate care, we aim to contribute significantly to the well-being of patients worldwide, offering them much-needed relief and hope for a better future. </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to achieve our goal, we have and will continue to build an experienced team of senior executives and scientists, with experience in all facets of pharmaceutical research and development, drug formulation, clinical trial execution and regulatory submissions. We intend to leverage the knowledge of our team in order to complete the clinical trials needed to receive approvals of our product candidates from applicable regulatory authorities.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initially, we intend to obtain approvals for our product candidates from the FDA and the Medical Cannabis Unit of the Israeli Ministry of Health, or MOH. Upon obtaining FDA approvals, or in the event that we are not successful in obtaining such approvals, we intend to apply for EMA and other countries’ governmental regulatory agencies approvals for our product candidates. If we are successful in obtaining FDA approvals for our product candidates, we intend to enter into royalty agreements with good manufacturing practice, or GMP, approved medical manufactures and distributors, having them using our medical formulas for the purpose of growing, cultivating, manufacturing, and distributing Raphael Pharmaceutical medical indications in their designated territories. </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements are prepared in accordance with U.S. GAAP. There are no critical accounting estimates for the years ended December 31, 2022 and 2021. Also, please see Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Page; Sequence: 12; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Three months ended June 30, 2023 compared to the three months ended June 30, 2022</i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Revenues</i>. We had no revenues during the three months ended June 30, 2023 and June 30, 2022.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Research and Development Expenses</i>. Our research and development expenses totaled $293,000 for the three months ended June 30, 2023, representing an increase of $209,000, or 248%, compared to $84,000 for the three months ended June 30, 2022. The increase was primarily attributable to value of shares issued to Wolc in June 2023.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>General and Administrative Expenses</i>. Our general and administrative expenses totaled $126,000 for the three months ended June 30, 2023, representing a decrease of $402,000, or 76%, compared to $528,000 for the three months ended June 30, 2022. The decrease was primarily due to the value of the shares and warrants issued to our former director for his services in June 2022.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Operating Loss</i>. Our operating loss totaled $419,000 for the three months ended June 30, 2023, representing a decrease of $193,000, or 31%, compared to $612,000 for the three months ended June 30, 2022. The decrease was primarily due to the decrease in our general and administrative expenses offset by an increase in our research and development expenses.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Financial Expense. </i>We recognized financial income, net, of $2,000 for the three months ended June 30, 2023, representing a decrease of $17,000, or 113,000%, compared to financial expense of $15,000 for the three months ended June 30, 2022. The decrease was primarily due to exchange rate differences between the U.S. dollar and New Israeli Shekel.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Net Loss</i>. As a result of the foregoing, our net loss totaled $417,000 for the three months ended June 30, 2023, representing a decrease of 210,000, or 33%, compared to $627,000 for the three months ended June 30, 2022. The decrease was primarily due to decrease in Company’s general and administrative expenses offset by an increase in Company’s research and development expenses.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Six months ended June 30, 2023 compared to the six months ended June 30, 2022</i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i> </i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Revenues</i>. We had no revenues during the six months ended June 30, 2023 and June 30, 2022.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Research and Development Expenses</i>. Our research and development expenses totaled $407,000 for the six months ended June 30, 2023, representing an increase of $237,000, or 139%, compared to $170,000 for the six months ended June 30, 2022. The increase was primarily attributable to the value of shares issued to Wolc in June 2023.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>General and Administrative Expenses</i>. Our general and administrative expenses totaled $270,000 for the six months ended June 30, 2023, representing a decrease of $347,000, or 56%, compared to $617,000 for the six months ended June 30, 2022. The decrease was primarily due to the value of shares and warrants issued to our former director for his services in June 2022.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div> </div><!-- Field: Page; Sequence: 13; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Operating Loss</i>. Our operating loss totaled $677,000 for the six months ended June 30, 2023, representing a decrease of $110,000, or 14%, compared to $787,000 for the six months ended June 30, 2022. The decrease was primarily due to the decrease in our general and administrative expenses offset by an increase in our research and development expenses.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Financial Expense. </i>We recognized financial expense of $4,000 for the six months ended June 30, 2023, representing a decrease of $21,000, or 84%, compared to $25,000 for the six months ended June 30, 2022. The decrease was primarily due to exchange rate differences between the U.S. dollar and New Israeli Shekel.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Net Loss</i>. As a result of the foregoing, our net loss totaled $681,000 for the six months ended June 30, 2023, representing a decrease of $131,000, or 16%, compared to $812,000 for the six months ended June 30, 2022. The decrease was primarily due to the decrease in our general and administrative expenses offset by an increase in our research and development expenses.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have funded our operations primarily through our founder’s capital and capital received from Easy Energy, Inc. As of June 30, 2023, we had $111,000 in cash and cash equivalents, and have invested most of our available cash funds in ongoing cash accounts.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">Net cash used in operating activities was $614,000 for the six months period ended June 30, 2023, compared with net cash used in operating activities of $330,000 for the corresponding period in 2022. The $284,000 increase in the net cash used in operating activities during the six months period ended June 30, 2023, compared to the same period in 2022, was primarily the result of payments made to our service providers following the receipt of funds from the issuance of shares and warrants.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">There was no net cash used in investing activities for the six months period ended June 30, 2023 and for the same period in 2022.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">Net cash provided by financing activities for the six months period ended June 30, 2023 was $437,000 compared to $312,000 for the same period in 2022. The increase in net cash provided by financing activities during the six months period ended June 30, 20223 compared to the corresponding period in 2022 was mainly due to the advance payment on account of shares to be received in 2023.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off Balance Sheet Arrangements</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rambam Research Agreement</i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a research agreement with Rambam Med-Tech Ltd, or Rambam MT, entered into by the parties in July 2019, or the Research Agreement, the Company agreed to fund a research project, to be performed by Rambam MT, with a research plan aimed at identifying the effects of different cannabis strains on the function of immune cells. On October 28, 2020, the Company and Rambam MT agreed to expand the research plan to study the anti-inflammatory activities of cannabis extracts in an RA mouse model. On February 15, 2021, the Company and Rambam MT agreed to further expand the research plan to study the effect of cannabis extracts on the immunopathology of the COVID-19 disease. The initial term of the Research Agreement was 48 months. On October 24, 2022, the Company and Rambam MT entered into a supplement to the Research Agreement, or the Supplement Agreement, pursuant to which the Company exercised an option to extend the Research Agreement by additional two years.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Research Agreement, we agreed to pay Rambam MT $1.4 million in four equal payments, due on the first day of August on each successive year from 2019 through 2022. Pursuant to the Supplement Agreement, we agreed to pay Rambam MT $960,000 plus VAT in four biannual payments from May 2023 through December 2024. Furthermore, in accordance with the terms of the Research Agreement, we and Rambam MT will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Rambam MT agreed not to work, study or develop any technologies with other entities that compete with our work with Rambam MT for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div> </div><!-- Field: Page; Sequence: 14; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to commercial sales of any product candidate using the IP created as a part of the research covered by such agreement, Raphael Israel is required to pay Rambam MT a royalty in an amount equal to 6% of all net sales, subject to certain deductions, such as taxes paid by any purchaser, transportation and shipping costs, and other customary deductions.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, the Company has made four of the four equal payments due pursuant to the Research Agreement, for a total amount of $1.4 million.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Way of Life Cannabis Agreement</i></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2020, Raphael Israel entered into an engagement agreement with Wolc, pursuant to which, subject to its completing the Share Exchange with Easy Energy, Raphael Israel will be provided with up to 15 liters of CBD oil, from a strain of cannabis during a term of 18 months, to be provided in two to three deliveries of between one to seven milliliters of CBD oil. In accordance with Raphael Israel’s agreement with Wolc, Raphael Israel has agreed to issue to certain persons affiliated with Wolc 3% of Raphael’s issued and outstanding share capital as of the date of the Share Exchange, to be provided in three equal issuances; provided, however, that such persons may elect to receive a cash payment of $100,000 instead of any one issuance of Raphael’s shares. In addition to the issuance of shares, Raphael Israel has also agreed to pay Wolc a royalty fee equal to 15% of the net royalties generated from sales of Raphael Israel’s pharmaceutical drug products that are developed at Rambam hospital in Israel.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 27, 2022, we issued 100,500 shares of common stock to Wolc in connection with the engagement agreement. The value of such issued shares was based on the value of the service provided, which amounted to $100,000. In June 2023, we issued the remining 201,000 shares of common stock to Wolc in connection with the services agreement dated October 2020.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for the above, we have not engaged in any off-balance sheet arrangements, such as the use of unconsolidated subsidiaries, structured finance, special purpose entities or variable interest entities.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that our off-balance sheet arrangements and commitments have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current Outlook</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations to date primarily through proceeds from our founder’s capital and capital received from Easy Energy. We have incurred losses and generated negative cash flows from operations since inception in 2019. To date we have not generated revenue, and we do not expect to generate significant revenues from the sale of our products in the near future.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this prospectus.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, our cash and cash equivalents were $111,000. We believe that our existing cash and cash equivalents will not be sufficient to fund our projected cash requirements through 2023. Therefore, we will require significant additional financing in the near future to fund our operations. We currently anticipate that we will require approximately $1 million for research and development activities over the course of the next 12 months. We also anticipate that we will require approximately $0.8 million for capital expenditures over such 12-month period, which consists primarily of expenditures for clinical trials and general Company operating costs.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div> </div><!-- Field: Page; Sequence: 15; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including: </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our research and development efforts, including our ability to finish research and development projects or product development within the allotted or expected timeline;</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of seeking to commercialize our products in a timely manner;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to generate cash flows;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government regulation in our industry, and more specifically, the costs and timing of obtaining regulatory approval or permits to launch our technology in various geographical markets; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of, and timing for, strengthening our manufacturing agreements for production of our wave energy systems.</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">   </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through our existing cash, cash equivalents and short-term deposits, loans, or debt or equity financings. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our products. This may raise substantial doubts about our ability to continue as a going concern.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Controls and Procedures</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of June 30, 2023.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial Reporting</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div> </div><!-- Field: Page; Sequence: 16; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II - OTHER INFORMATION</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Legal Proceedings</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been no material changes to our legal proceedings as described in “Item 3. Legal Proceedings” in our Annual Report on Form 10-K, as amended, filed with the SEC on March 24, 2023.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><div> </div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1A. Risk Factors</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been no material changes to our risk factors from those disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K, as amended, filed with the SEC on March 24, 2023.  </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 6. Exhibits</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td> <td style="width: 1%; text-align: justify"> </td> <td style="width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0623ex31-1_raphael.htm">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).</a></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0623ex31-2_raphael.htm">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).</a></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0623ex32-1_raphael.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.</a></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0623ex32-2_raphael.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.</a></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Page; Sequence: 17; Value: 1 --><div> </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div> </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div><div> </div><!-- Field: /Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RAPHAEL PHARMACEUTICAL INC.</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td colspan="2" style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 9, 2023</span></td> <td style="text-align: justify; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td> <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shlomo Pilo</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:  </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Pilo </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<br/> (Principal Executive Officer)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 9, 2023</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Guy Ofir                    </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Ofir</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial Officer)</p></td></tr> </table><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8</p><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div> </div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"> </div></div><!-- Field: /Rule-Page --><div> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div> </div><div style="display: none"><ix:header> <ix:hidden> <ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-0" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.03</ix:nonFraction> <ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-1" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.04</ix:nonFraction> <ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-2" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.05</ix:nonFraction> <ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-3" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.06</ix:nonFraction> <ix:nonFraction contextRef="c4" decimals="INF" id="hidden-fact-4" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">13342679</ix:nonFraction> <ix:nonFraction contextRef="c6" decimals="INF" id="hidden-fact-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">13647151</ix:nonFraction> <ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">16037214</ix:nonFraction> <ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">16109514</ix:nonFraction> <ix:nonFraction contextRef="c12" id="hidden-fact-8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c10" id="hidden-fact-9" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c11" id="hidden-fact-10" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c20" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c20" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c18" id="hidden-fact-13" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c19" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c30" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c28" id="hidden-fact-16" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c29" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c36" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c37" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c4" id="hidden-fact-20" name="us-gaap:Depreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonFraction contextRef="c4" id="hidden-fact-21" name="raph:AdvancePaymentOnAccountOfShares" unitRef="usd" xsi:nil="true"></ix:nonFraction> <ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001415397</ix:nonNumeric> </ix:hidden> <ix:references><link:schemaRef xlink:href="raph-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references> <ix:resources><xbrli:context id="c0"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c2"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c3"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c4"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c5"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c6"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c7"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c8"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c9"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c13"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c17"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c19"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c20"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c22"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c23"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c27"> <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbFKbUB4dxGpkl7XoM46zsM2As3AH8cJOG3l573Dm3ZfHzTdfq5Tafuqlfo2kjyiss414qF8SLkhO+mQvto8ILjupUcex9RKtfQBgsT5tkmjQoV/U4IZEDbFoC+X5z4XrOguEax0RVVX+F05uhREplt8+gn29p0P16r1mpXBtoLJa3Os3nlYpqrWn4qmn8ejbkg7AWTFFjynaZc0xdSemTw1mHVaGAD+H8=] CSR--> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c28"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c29"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c30"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c32"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c33"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c34"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c35"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c36"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c37"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c38"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c39"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c40"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c41"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c42"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c43"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-08</xbrli:startDate> <xbrli:endDate>2020-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c44"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c45"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-14</xbrli:startDate> <xbrli:endDate>2021-05-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c46"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c47"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-30</xbrli:startDate> <xbrli:endDate>2022-12-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c48"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c49"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-08</xbrli:startDate> <xbrli:endDate>2023-01-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c50"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c51"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c52"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="c53"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-31</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c54"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-30</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="c55"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001415397</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-01</xbrli:startDate> <xbrli:endDate>2023-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:unit id="shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="usd"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="usdPershares"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit></ix:resources></ix:header> </div></div></body> </html> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.1 <SEQUENCE>2 <FILENAME>f10q0623ex31-1_raphael.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B> </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Shlomo Pilo, certify that:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this quarterly report on Form 10-Q of Raphael Pharmaceutical Inc.;</TD> </TR></TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD> </TR></TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD> </TR></TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD> </TR></TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’s internal control over financial reporting; and</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR> <TD STYLE="text-align: justify; vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 9, 2023</FONT></TD> <TD STYLE="text-align: justify; vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD> <TD STYLE="text-align: justify; vertical-align: top; width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shlomo Pilo</FONT></TD></TR> <TR> <TD STYLE="text-align: justify; vertical-align: top"> </TD> <TD STYLE="text-align: justify; vertical-align: bottom"> </TD> <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Pilo</FONT></TD></TR> <TR> <TD STYLE="text-align: justify; vertical-align: top"> </TD> <TD STYLE="text-align: justify; vertical-align: bottom"> </TD> <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR> </TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.2 <SEQUENCE>3 <FILENAME>f10q0623ex31-2_raphael.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Guy Ofir, certify that:</P> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this quarterly report on Form 10-Q of Raphael Pharmaceutical Inc.;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’s internal control over financial reporting; and</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"> <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</TD> </TR></TABLE> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR> <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 9, 2023</FONT></TD> <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD> <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Guy Ofir</FONT></TD></TR> <TR> <TD STYLE="vertical-align: top"> </TD> <TD STYLE="vertical-align: bottom"> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Ofir</FONT></TD></TR> <TR> <TD STYLE="vertical-align: top"> </TD> <TD STYLE="vertical-align: bottom"> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.1 <SEQUENCE>4 <FILENAME>f10q0623ex32-1_raphael.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the quarterly report of Raphael Pharmaceutical Inc., or the Company, on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Shlomo Pilo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD> <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD> <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 9, 2023</FONT></TD> <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shlomo Pilo</FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Pilo</FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.2 <SEQUENCE>5 <FILENAME>f10q0623ex32-2_raphael.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the quarterly report of Raphael Pharmaceutical Inc., or the Company, on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Guy Ofir, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD> <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD> <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 9, 2023</FONT></TD> <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Guy Ofir</FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Ofir</FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>6 <FILENAME>raph-20230630.xsd <DESCRIPTION>XBRL SCHEMA FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --> <!-- Created: Tue Aug 08 05:06:14 UTC 2023 --> <xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:raph="http://www.raphaelpharmaceutical.com/20230630" targetNamespace="http://www.raphaelpharmaceutical.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance"> <xs:annotation> <xs:appinfo> <link:linkbaseRef xlink:type="simple" xlink:href="raph-20230630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/> <link:linkbaseRef xlink:type="simple" xlink:href="raph-20230630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/> <link:linkbaseRef xlink:type="simple" xlink:href="raph-20230630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/> <link:linkbaseRef xlink:type="simple" xlink:href="raph-20230630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" id="raph_r_ConsolidatedBalanceSheet"> <link:definition>001 - Statement - Condensed Consolidated Interim Balance Sheets</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals" id="raph_r_ConsolidatedBalanceSheet_Parentheticals"> <link:definition>002 - Statement - Condensed Consolidated Interim Balance Sheets (Parentheticals)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" id="raph_r_ConsolidatedIncomeStatement"> <link:definition>003 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals" id="raph_r_ConsolidatedIncomeStatement_Parentheticals"> <link:definition>004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss (Parentheticals)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" id="raph_r_ShareholdersEquityType2or3"> <link:definition>005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" id="raph_r_ConsolidatedCashFlow"> <link:definition>006 - Statement - Condensed Consolidated Interim Statements of Cash Flows</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/General" id="raph_r_General"> <link:definition>007 - Disclosure - General</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies" id="raph_r_SignificantAccountingPolicies"> <link:definition>008 - Disclosure - Significant Accounting Policies</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements" id="raph_r_UnauditedInterimFinancialStatements"> <link:definition>009 - Disclosure - Unaudited Interim Financial Statements</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquity" id="raph_r_ShareholdersEquity"> <link:definition>010 - Disclosure - Shareholders’ Equity</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbFKbUB4dxGpkl7XoM46zsM2As3AH8cJOG3l573Dm3ZfHzTdfq5Tafuqlfo2kjyiss414qF8SLkhO+mQvto8ILjupUcex9RKtfQBgsT5tkmjQoV/U4IZEDbFoC+X5z4XrOguEax0RVVX+F05uhREplt8+gn29p0P16r1mpXBtoLJa3Os3nlYpqrWn4qmn8ejbkg7AWTFFjynRNUME2vSZLNxlYW9deHzLBLvUducYAdow==] CSR--> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/GeneralDetails" id="raph_r_GeneralDetails"> <link:definition>011 - Disclosure - General (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" id="raph_r_ShareholdersEquityDetails"> <link:definition>012 - Disclosure - Shareholders’ Equity (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation"> <link:definition>000 - Document - Document And Entity Information</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> </link:roleType> </xs:appinfo> </xs:annotation> <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/> <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/> <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/> <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/> <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/> <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/> <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/> <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract"/> <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract0"/> <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract1"/> <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract2"/> <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract3"/> <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract4"/> <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract5"/> <xs:element name="CommonStock001ParValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_CommonStock001ParValueAbstract"/> <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract6"/> <xs:element name="Authorized21020560SharesAtJune302023AndDecember312022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract"/> <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract7"/> <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract8"/> <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract9"/> <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract10"/> <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract11"/> <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract12"/> <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract13"/> <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract14"/> <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract15"/> <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract16"/> <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract17"/> <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract18"/> <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract19"/> <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract20"/> <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract21"/> <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract22"/> <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract23"/> <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract24"/> <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract25"/> <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract26"/> <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract27"/> <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract28"/> <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract29"/> <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract30"/> <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_UnlabeledAbstract31"/> <xs:element name="AdvancePaymentOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="raph_AdvancePaymentOnAccountOfShares"/> <xs:element name="IssuedAndOutstandingShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_IssuedAndOutstandingShareCapitalPercentage"/> <xs:element name="CommonStockPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_CommonStockPercentage"/> <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="raph_ShareholdersEquityDetailsTable"/> <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_ShareholdersEquityDetailsLineItems"/> <xs:element name="CompanyRaisedPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_CompanyRaisedPricePerShare"/> <xs:element name="PurchaseWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_PurchaseWarrants"/> <xs:element name="CompanyRaisedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="raph_CompanyRaisedAmount"/> <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="raph_DocumentAndEntityInformationAbstract"/> </xs:schema> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.CAL <SEQUENCE>7 <FILENAME>raph-20230630_cal.xml <DESCRIPTION>XBRL CALCULATION FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --> <!-- Created: Tue Aug 08 05:06:14 UTC 2023 --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedBalanceSheet" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedIncomeStatement" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedCashFlow" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow"/> <calculationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet"> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/> <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/> <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="2" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/> </calculationLink> <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbFKbUB4dxGpkl7XoM46zsM2As3AH8cJOG3l573Dm3ZfHzTdfq5Tafuqlfo2kjyiss414qF8SLkhO+mQvto8ILjupUcex9RKtfQBgsT5tkmjQoV/U4IZEDbFoC+X5z4XrOguEax0RVVX+F05uhREplt8+gn29p0P16r1mpXBtoLJa3Os3nlYpqrWn4qmn8ejbkg7AWTFFjynZ0gF3zxKeGtFLQ7GgovI4kpZA3yzD8BGQ==] CSR--> <calculationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement"> <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/> <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/> <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1"/> <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow"> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/> <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="3" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="4" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="5" weight="-1"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/> <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/> <loc xlink:type="locator" xlink:label="raph_AdvancePaymentOnAccountOfShares" xlink:href="raph-20230630.xsd#raph_AdvancePaymentOnAccountOfShares"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="raph_AdvancePaymentOnAccountOfShares" order="2" weight="1"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1"/> </calculationLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>8 <FILENAME>raph-20230630_def.xml <DESCRIPTION>XBRL DEFINITION FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --> <!-- Created: Tue Aug 08 05:06:14 UTC 2023 --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt"> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedBalanceSheet" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedIncomeStatement" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ShareholdersEquityType2or3" roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedCashFlow" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_General" roleURI="http://www.raphaelpharmaceutical.com/role/General"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_SignificantAccountingPolicies" roleURI="http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_UnauditedInterimFinancialStatements" roleURI="http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ShareholdersEquity" roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquity"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_GeneralDetails" roleURI="http://www.raphaelpharmaceutical.com/role/GeneralDetails"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ShareholdersEquityDetails" roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#DocumentAndEntityInformation" roleURI="http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement"> <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals"> <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3"> <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/> <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbFKbUB4dxGpkl7XoM46zsM2As3AH8cJOG3l573Dm3ZfHzTdfq5Tafuqlfo2kjyiss414qF8SLkhO+mQvto8ILjupUcex9RKtfQBgsT5tkmjQoV/U4IZEDbFoC+X5z4XrOguEax0RVVX+F05uhREplt8+gn29p0P16r1mpXBtoLJa3Os3nlYpqrWn4qmn8ejbkg7AWTFFjynUlGgMEpMV4woyKx98MDw+D6rH8bemDmdw==] CSR--> <loc xlink:type="locator" xlink:label="raph_AdvancePaymentOnAccountOfShares" xlink:href="raph-20230630.xsd#raph_AdvancePaymentOnAccountOfShares"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="raph_AdvancePaymentOnAccountOfShares" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/General"> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies"> <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements"> <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/> <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsTextBlock"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialStatementsTextBlock" order="0" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ShareholdersEquity"> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/GeneralDetails"> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <loc xlink:type="locator" xlink:label="raph_IssuedAndOutstandingShareCapitalPercentage" xlink:href="raph-20230630.xsd#raph_IssuedAndOutstandingShareCapitalPercentage"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="raph_IssuedAndOutstandingShareCapitalPercentage" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="raph_CommonStockPercentage" xlink:href="raph-20230630.xsd#raph_CommonStockPercentage"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="raph_CommonStockPercentage" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SharesIssued" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsUnappropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsUnappropriated"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsUnappropriated" order="6" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails"> <loc xlink:type="locator" xlink:label="raph_ShareholdersEquityDetailsLineItems" xlink:href="raph-20230630.xsd#raph_ShareholdersEquityDetailsLineItems"/> <loc xlink:type="locator" xlink:label="raph_ShareholdersEquityDetailsTable" xlink:href="raph-20230630.xsd#raph_ShareholdersEquityDetailsTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="raph_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="raph_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="raph_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="raph_CompanyRaisedPricePerShare" xlink:href="raph-20230630.xsd#raph_CompanyRaisedPricePerShare"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="raph_CompanyRaisedPricePerShare" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="raph_PurchaseWarrants" xlink:href="raph-20230630.xsd#raph_PurchaseWarrants"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="raph_PurchaseWarrants" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="raph_CompanyRaisedAmount" xlink:href="raph-20230630.xsd#raph_CompanyRaisedAmount"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="raph_CompanyRaisedAmount" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="7" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" order="8" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherValueOutstanding"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockOtherValueOutstanding" order="9" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_TransferToInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferToInvestments"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_TransferToInvestments" order="10" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="11" xbrldt:closed="true"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation"> <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/> <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="15" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="16" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="17" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="18" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="19" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="20" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="21" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="22" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="23" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="24" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="25" xbrldt:closed="true"/> <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="26" xbrldt:closed="true"/> </definitionLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>9 <FILENAME>raph-20230630_lab.xml <DESCRIPTION>XBRL LABEL FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --> <!-- Created: Tue Aug 08 05:06:14 UTC 2023 --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link"> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders’ equity (deficit)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders’ equity (deficit)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Change in cash and cash equivalents</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the period</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/> <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xml:lang="en-US">Unaudited Interim Financial Statements [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Shareholders’ Equity [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/> <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/> <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/> <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/> <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/> <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/> <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/> <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/> <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/> <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/> <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/> <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract" xlink:to="raph_UnlabeledAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract0" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract0_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract0" xlink:to="raph_UnlabeledAbstract0_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Fixed assets, net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract1" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract1_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract1" xlink:to="raph_UnlabeledAbstract1_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract2" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract2"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract2_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract2" xlink:to="raph_UnlabeledAbstract2_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders’ equity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract3" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract3"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract3_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract3" xlink:to="raph_UnlabeledAbstract3_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other account payables and accrued expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Payable to related party</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract4" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract4"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract4_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract4" xlink:to="raph_UnlabeledAbstract4_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract5" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract5"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract5_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract5" xlink:to="raph_UnlabeledAbstract5_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders’ equity (deficit):</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_CommonStock001ParValueAbstract" xlink:href="raph-20230630.xsd#raph_CommonStock001ParValueAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_CommonStock001ParValueAbstract_lbl" xml:lang="en-US">Common stock, $0.01 par value:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CommonStock001ParValueAbstract" xlink:to="raph_CommonStock001ParValueAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract6" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract6"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract6_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract6" xlink:to="raph_UnlabeledAbstract6_lbl"/> <loc xlink:type="locator" xlink:label="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract" xlink:href="raph-20230630.xsd#raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract_lbl" xml:lang="en-US">Authorized: 21,020,560 shares at June 30, 2023 and December 31, 2022;</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract" xlink:to="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract7" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract7"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract7_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract7" xlink:to="raph_UnlabeledAbstract7_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value:Authorized: 21,020,560 shares at June 30, 2023 and December 31, 2022;Issued and outstanding: 16,368,168 and 15,624,040 at June 30, 2023 and December 31, 2022, respectively;</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock, shares, issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common stock share issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common stock, shares, outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract8" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract8"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract8_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract8" xlink:to="raph_UnlabeledAbstract8_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract9" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract9"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract9_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract9" xlink:to="raph_UnlabeledAbstract9_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract10" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract10"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract10_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract10" xlink:to="raph_UnlabeledAbstract10_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract11" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract11"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract11_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract11" xlink:to="raph_UnlabeledAbstract11_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract12" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract12"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract12_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract12" xlink:to="raph_UnlabeledAbstract12_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract13" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract13"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract13_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract13" xlink:to="raph_UnlabeledAbstract13_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract14" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract14"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract14_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract14" xlink:to="raph_UnlabeledAbstract14_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract15" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract15"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract15_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract15" xlink:to="raph_UnlabeledAbstract15_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares of common stock used in computing basic net loss per share (in Shares)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares used in computing diluted net loss per share (in Shares)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract16" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract16"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract16_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract16" xlink:to="raph_UnlabeledAbstract16_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock and warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock and warrants (in Shares)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract17" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract17"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract17_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract17" xlink:to="raph_UnlabeledAbstract17_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract18" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract18"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract18_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract18" xlink:to="raph_UnlabeledAbstract18_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock in exchange for services</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock in exchange for services (in Shares)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract19" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract19"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract19_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract19" xlink:to="raph_UnlabeledAbstract19_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract20" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract20"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract20_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract20" xlink:to="raph_UnlabeledAbstract20_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract21" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract21"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract21_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract21" xlink:to="raph_UnlabeledAbstract21_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract22" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract22"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract22_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract22" xlink:to="raph_UnlabeledAbstract22_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract23" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract23"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract23_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract23" xlink:to="raph_UnlabeledAbstract23_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract24" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract24"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract24_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract24" xlink:to="raph_UnlabeledAbstract24_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract25" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract25"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract25_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract25" xlink:to="raph_UnlabeledAbstract25_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based payment in exchange for services</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract26" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract26"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract26_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract26" xlink:to="raph_UnlabeledAbstract26_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Account payables and related party</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract27" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract27"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract27_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract27" xlink:to="raph_UnlabeledAbstract27_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract28" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract28"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract28_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract28" xlink:to="raph_UnlabeledAbstract28_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract29" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract29"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract29_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract29" xlink:to="raph_UnlabeledAbstract29_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock and warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/> <loc xlink:type="locator" xlink:label="raph_AdvancePaymentOnAccountOfShares" xlink:href="raph-20230630.xsd#raph_AdvancePaymentOnAccountOfShares"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_AdvancePaymentOnAccountOfShares_lbl" xml:lang="en-US">Advance payment on account of shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_AdvancePaymentOnAccountOfShares" xlink:to="raph_AdvancePaymentOnAccountOfShares_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract30" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract30"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract30_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract30" xlink:to="raph_UnlabeledAbstract30_lbl"/> <loc xlink:type="locator" xlink:label="raph_UnlabeledAbstract31" xlink:href="raph-20230630.xsd#raph_UnlabeledAbstract31"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_UnlabeledAbstract31_lbl" xml:lang="en-US"></label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract31" xlink:to="raph_UnlabeledAbstract31_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total financial expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/> <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbFKbUB4dxGpkl7XoM46zsM2As3AH8cJOG3l573Dm3ZfHzTdfq5Tafuqlfo2kjyiss414qF8SLkhO+mQvto8ILjupUcex9RKtfQBgsT5tkmjQoV/U4IZEDbFoC+X5z4XrOguEax0RVVX+F05uhREplt8+gn29p0P16r1mpXBtoLJa3Os3nlYpqrWn4qmn8ejbkg7AWTFFjynbLVhLTgLjnYqirOxtKhZJ4DxA56qKy+gw==] CSR--> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/> <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedFinancialStatementsTextBlock_lbl" xml:lang="en-US">UNAUDITED INTERIM FINANCIAL STATEMENTS</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsTextBlock" xlink:to="srt_CondensedFinancialStatementsTextBlock_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS’ EQUITY</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/> <loc xlink:type="locator" xlink:label="raph_IssuedAndOutstandingShareCapitalPercentage" xlink:href="raph-20230630.xsd#raph_IssuedAndOutstandingShareCapitalPercentage"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_IssuedAndOutstandingShareCapitalPercentage_lbl" xml:lang="en-US">Issued and outstanding share capital percentage</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_IssuedAndOutstandingShareCapitalPercentage" xlink:to="raph_IssuedAndOutstandingShareCapitalPercentage_lbl"/> <loc xlink:type="locator" xlink:label="raph_CommonStockPercentage" xlink:href="raph-20230630.xsd#raph_CommonStockPercentage"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_CommonStockPercentage_lbl" xml:lang="en-US">Common stock percentage</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CommonStockPercentage" xlink:to="raph_CommonStockPercentage_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Shares issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Share exchange common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsUnappropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsUnappropriated"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsUnappropriated_lbl" xml:lang="en-US">Accumulated deficit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsUnappropriated" xlink:to="us-gaap_RetainedEarningsUnappropriated_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Shares issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/> <loc xlink:type="locator" xlink:label="raph_CompanyRaisedPricePerShare" xlink:href="raph-20230630.xsd#raph_CompanyRaisedPricePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_CompanyRaisedPricePerShare_lbl" xml:lang="en-US">Company raised price per share (in Dollars per share)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CompanyRaisedPricePerShare" xlink:to="raph_CompanyRaisedPricePerShare_lbl"/> <loc xlink:type="locator" xlink:label="raph_PurchaseWarrants" xlink:href="raph-20230630.xsd#raph_PurchaseWarrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_PurchaseWarrants_lbl" xml:lang="en-US">Warrants purchase</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_PurchaseWarrants" xlink:to="raph_PurchaseWarrants_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/> <loc xlink:type="locator" xlink:label="raph_CompanyRaisedAmount" xlink:href="raph-20230630.xsd#raph_CompanyRaisedAmount"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="raph_CompanyRaisedAmount_lbl" xml:lang="en-US">Company raised amount (in Dollars)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CompanyRaisedAmount" xlink:to="raph_CompanyRaisedAmount_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Agreed amount (in Dollars)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" xml:lang="en-US">Investment amount (in Dollars)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherValueOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherValueOutstanding_lbl" xml:lang="en-US">Amount received (in Dollars)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherValueOutstanding" xlink:to="us-gaap_CommonStockOtherValueOutstanding_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_TransferToInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferToInvestments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransferToInvestments_lbl" xml:lang="en-US">Investor transferred (in Dollars)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferToInvestments" xlink:to="us-gaap_TransferToInvestments_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Service provided (in Dollars)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/> <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/> <loc xlink:type="locator" xlink:label="raph_ShareholdersEquityDetailsTable" xlink:href="raph-20230630.xsd#raph_ShareholdersEquityDetailsTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders’ Equity (Details) [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_ShareholdersEquityDetailsTable" xlink:to="raph_ShareholdersEquityDetailsTable_lbl"/> <loc xlink:type="locator" xlink:label="raph_ShareholdersEquityDetailsLineItems" xlink:href="raph-20230630.xsd#raph_ShareholdersEquityDetailsLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders’ Equity (Details) [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_ShareholdersEquityDetailsLineItems" xlink:to="raph_ShareholdersEquityDetailsLineItems_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="raph_AdvancePaymentOnAccountOfShares_lbl0" xml:lang="en-US">Advance payment on account of shares.</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_AdvancePaymentOnAccountOfShares" xlink:to="raph_AdvancePaymentOnAccountOfShares_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="raph_CommonStockPercentage_lbl0" xml:lang="en-US">Common stock percentage.</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CommonStockPercentage" xlink:to="raph_CommonStockPercentage_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="raph_CompanyRaisedAmount_lbl0" xml:lang="en-US">Company raised amount.</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CompanyRaisedAmount" xlink:to="raph_CompanyRaisedAmount_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="raph_CompanyRaisedPricePerShare_lbl0" xml:lang="en-US">Company raised price per share.</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CompanyRaisedPricePerShare" xlink:to="raph_CompanyRaisedPricePerShare_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="raph_IssuedAndOutstandingShareCapitalPercentage_lbl0" xml:lang="en-US">Issued and Outstanding Share Capital percentage.</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_IssuedAndOutstandingShareCapitalPercentage" xlink:to="raph_IssuedAndOutstandingShareCapitalPercentage_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="raph_PurchaseWarrants_lbl0" xml:lang="en-US">The value of purchase warrants.</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_PurchaseWarrants" xlink:to="raph_PurchaseWarrants_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_IssuedAndOutstandingShareCapitalPercentage_lbl1" xml:lang="en-US">Issued And Outstanding Share Capital Percentage</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_IssuedAndOutstandingShareCapitalPercentage" xlink:to="raph_IssuedAndOutstandingShareCapitalPercentage_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract2" xlink:to="raph_UnlabeledAbstract2_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_CompanyRaisedAmount_lbl1" xml:lang="en-US">Company Raised Amount</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CompanyRaisedAmount" xlink:to="raph_CompanyRaisedAmount_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract1" xlink:to="raph_UnlabeledAbstract1_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract4" xlink:to="raph_UnlabeledAbstract4_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract3" xlink:to="raph_UnlabeledAbstract3_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract0" xlink:to="raph_UnlabeledAbstract0_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract9" xlink:to="raph_UnlabeledAbstract9_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_CommonStockPercentage_lbl1" xml:lang="en-US">Common Stock Percentage</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CommonStockPercentage" xlink:to="raph_CommonStockPercentage_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl0" xml:lang="en-US">Other Cost and Expense, Operating</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract6" xlink:to="raph_UnlabeledAbstract6_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract5" xlink:to="raph_UnlabeledAbstract5_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract8" xlink:to="raph_UnlabeledAbstract8_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract7" xlink:to="raph_UnlabeledAbstract7_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Text Block]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsTextBlock" xlink:to="srt_CondensedFinancialStatementsTextBlock_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract" xlink:to="raph_UnlabeledAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransferToInvestments_lbl0" xml:lang="en-US">Transfer to Investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferToInvestments" xlink:to="us-gaap_TransferToInvestments_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract18" xlink:to="raph_UnlabeledAbstract18_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract19" xlink:to="raph_UnlabeledAbstract19_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract16" xlink:to="raph_UnlabeledAbstract16_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract17" xlink:to="raph_UnlabeledAbstract17_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_CompanyRaisedPricePerShare_lbl1" xml:lang="en-US">Company Raised Price Per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CompanyRaisedPricePerShare" xlink:to="raph_CompanyRaisedPricePerShare_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_PurchaseWarrants_lbl1" xml:lang="en-US">Purchase Warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_PurchaseWarrants" xlink:to="raph_PurchaseWarrants_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract_lbl0" xml:lang="en-US">Authorized21020560 Shares At June302023 And December312022 Abstract</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract" xlink:to="raph_Authorized21020560SharesAtJune302023AndDecember312022Abstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract21" xlink:to="raph_UnlabeledAbstract21_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract22" xlink:to="raph_UnlabeledAbstract22_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract20" xlink:to="raph_UnlabeledAbstract20_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract25" xlink:to="raph_UnlabeledAbstract25_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract26" xlink:to="raph_UnlabeledAbstract26_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract23" xlink:to="raph_UnlabeledAbstract23_lbl0"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract24" xlink:to="raph_UnlabeledAbstract24_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract29" xlink:to="raph_UnlabeledAbstract29_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract27" xlink:to="raph_UnlabeledAbstract27_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract28" xlink:to="raph_UnlabeledAbstract28_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl2" xml:lang="en-US">Common Stock, Shares, Issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl2"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl0" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherValueOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Value, Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherValueOutstanding" xlink:to="us-gaap_CommonStockOtherValueOutstanding_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract30" xlink:to="raph_UnlabeledAbstract30_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract31" xlink:to="raph_UnlabeledAbstract31_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_AdvancePaymentOnAccountOfShares_lbl1" xml:lang="en-US">Advance Payment On Account Of Shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_AdvancePaymentOnAccountOfShares" xlink:to="raph_AdvancePaymentOnAccountOfShares_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_CommonStock001ParValueAbstract_lbl0" xml:lang="en-US">Common Stock001 Par Value Abstract</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_CommonStock001ParValueAbstract" xlink:to="raph_CommonStock001ParValueAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl0" xml:lang="en-US">Equity Method Investment, Quoted Market Value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract10" xlink:to="raph_UnlabeledAbstract10_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract11" xlink:to="raph_UnlabeledAbstract11_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract14" xlink:to="raph_UnlabeledAbstract14_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract15" xlink:to="raph_UnlabeledAbstract15_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract12" xlink:to="raph_UnlabeledAbstract12_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="raph_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="raph_UnlabeledAbstract13" xlink:to="raph_UnlabeledAbstract13_lbl0"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsUnappropriated_lbl0" xml:lang="en-US">Retained Earnings, Unappropriated</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsUnappropriated" xlink:to="us-gaap_RetainedEarningsUnappropriated_lbl0"/> </labelLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>10 <FILENAME>raph-20230630_pre.xml <DESCRIPTION>XBRL PRESENTATION FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com --> <!-- Created: Tue Aug 08 05:06:14 UTC 2023 --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedBalanceSheet" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedIncomeStatement" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ShareholdersEquityType2or3" roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ConsolidatedCashFlow" roleURI="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_General" roleURI="http://www.raphaelpharmaceutical.com/role/General"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_SignificantAccountingPolicies" roleURI="http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_UnauditedInterimFinancialStatements" roleURI="http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ShareholdersEquity" roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquity"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_GeneralDetails" roleURI="http://www.raphaelpharmaceutical.com/role/GeneralDetails"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#raph_r_ShareholdersEquityDetails" roleURI="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails"/> <roleRef xlink:type="simple" xlink:href="raph-20230630.xsd#DocumentAndEntityInformation" roleURI="http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation"/> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement"> <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals"> <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow"> <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="AdvancePaymentOnAccountOfShares" xlink:href="raph-20230630.xsd#raph_AdvancePaymentOnAccountOfShares"/> <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbFKbUB4dxGpkl7XoM46zsM2As3AH8cJOG3l573Dm3ZfHzTdfq5Tafuqlfo2kjyiss414qF8SLkhO+mQvto8ILjupUcex9RKtfQBgsT5tkmjQoV/U4IZEDbFoC+X5z4XrOguEax0RVVX+F05uhREplt8+gn29p0P16r1mpXBtoLJa3Os3nlYpqrWn4qmn8ejbkg7AWTFFjynQq92ZhPs5bcLgP9WsppPpk=] CSR--> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="AdvancePaymentOnAccountOfShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/General"> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies"> <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements"> <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/> <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialStatementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ShareholdersEquity"> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/GeneralDetails"> <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <loc xlink:type="locator" xlink:label="IssuedAndOutstandingShareCapitalPercentage" xlink:href="raph-20230630.xsd#raph_IssuedAndOutstandingShareCapitalPercentage"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="IssuedAndOutstandingShareCapitalPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="CommonStockPercentage" xlink:href="raph-20230630.xsd#raph_CommonStockPercentage"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CommonStockPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsUnappropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsUnappropriated"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsUnappropriated" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails"> <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/> <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="raph-20230630.xsd#raph_ShareholdersEquityDetailsTable"/> <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="raph-20230630.xsd#raph_ShareholdersEquityDetailsLineItems"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/> <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/> <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="CompanyRaisedPricePerShare" xlink:href="raph-20230630.xsd#raph_CompanyRaisedPricePerShare"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CompanyRaisedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="PurchaseWarrants" xlink:href="raph-20230630.xsd#raph_PurchaseWarrants"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PurchaseWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="CompanyRaisedAmount" xlink:href="raph-20230630.xsd#raph_CompanyRaisedAmount"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CompanyRaisedAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherValueOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockOtherValueOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_TransferToInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferToInvestments"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_TransferToInvestments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation"> <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="raph-20230630.xsd#raph_DocumentAndEntityInformationAbstract"/> <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/> <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/> <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> </presentationLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>11 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834848624"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Aug. 09, 2023</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td> <td class="text">Raphael Pharmaceutical Inc.<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td> <td class="text">10-Q<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td> <td class="text">--12-31<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td> <td class="text"> <span></span> </td> <td class="nump">16,368,168<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td> <td class="text">0001415397<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td> <td class="text">Non-accelerated Filer<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td> <td class="text">Jun. 30, 2023<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td> <td class="text">2023<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td> <td class="text">Q2<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td> <td class="text">000-53002<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td> <td class="text">NV<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td> <td class="text">26-0204284<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td> <td class="text">4 Lui Paster Street<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td> <td class="text">Tel Aviv-Jaffa<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td> <td class="text">IL<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td> <td class="text">6803605<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td> <td class="text">(+972)<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td> <td class="text">52-775-5072<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AmendmentFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CityAreaCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gMonthDayItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fiscalPeriodItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentInformationLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentTransitionReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentType</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:submissionTypeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressCountry</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:countryCodeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:centralIndexKeyItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFileNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fileNumberItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFilerCategory</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:filerCategoryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarStateCountryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityRegistrantName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityShellCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntitySmallBusiness</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:employerIdItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LocalPhoneNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>12 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542832777040"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Dec. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump">$ 111<span></span> </td> <td class="nump">$ 288<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td> <td class="nump">7<span></span> </td> <td class="nump">43<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td> <td class="nump">118<span></span> </td> <td class="nump">331<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Fixed assets, net</a></td> <td class="nump">1<span></span> </td> <td class="nump">2<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td> <td class="nump">119<span></span> </td> <td class="nump">333<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other account payables and accrued expenses</a></td> <td class="nump">141<span></span> </td> <td class="nump">224<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Payable to related party</a></td> <td class="nump">39<span></span> </td> <td class="nump">3<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td> <td class="nump">180<span></span> </td> <td class="nump">227<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders’ equity (deficit):</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value:Authorized: 21,020,560 shares at June 30, 2023 and December 31, 2022;Issued and outstanding: 16,368,168 and 15,624,040 at June 30, 2023 and December 31, 2022, respectively;</a></td> <td class="nump">164<span></span> </td> <td class="nump">157<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td> <td class="nump">6,482<span></span> </td> <td class="nump">5,975<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="num">(6,707)<span></span> </td> <td class="num">(6,026)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders’ equity (deficit)</a></td> <td class="num">(61)<span></span> </td> <td class="nump">106<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders’ equity (deficit)</a></td> <td class="nump">$ 119<span></span> </td> <td class="nump">$ 333<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Assets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>13 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834052784"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Dec. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td> <td class="nump">$ 0.01<span></span> </td> <td class="nump">$ 0.01<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td> <td class="nump">21,020,560<span></span> </td> <td class="nump">21,020,560<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td> <td class="nump">16,368,168<span></span> </td> <td class="nump">15,624,040<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td> <td class="nump">16,368,168<span></span> </td> <td class="nump">15,624,040<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>14 <FILENAME>R4.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834814944"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Jun. 30, 2022</div></th> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Jun. 30, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td> <td class="nump">$ 293<span></span> </td> <td class="nump">$ 84<span></span> </td> <td class="nump">$ 407<span></span> </td> <td class="nump">$ 170<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td> <td class="nump">126<span></span> </td> <td class="nump">528<span></span> </td> <td class="nump">270<span></span> </td> <td class="nump">617<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td> <td class="nump">419<span></span> </td> <td class="nump">612<span></span> </td> <td class="nump">677<span></span> </td> <td class="nump">787<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financial expense</a></td> <td class="num">(2)<span></span> </td> <td class="nump">15<span></span> </td> <td class="nump">4<span></span> </td> <td class="nump">25<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">$ 417<span></span> </td> <td class="nump">$ 627<span></span> </td> <td class="nump">$ 681<span></span> </td> <td class="nump">$ 812<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td> <td class="nump">$ 0.03<span></span> </td> <td class="nump">$ 0.05<span></span> </td> <td class="nump">$ 0.04<span></span> </td> <td class="nump">$ 0.06<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares of common stock used in computing basic net loss per share (in Shares)</a></td> <td class="nump">16,109,514<span></span> </td> <td class="nump">13,647,151<span></span> </td> <td class="nump">16,037,214<span></span> </td> <td class="nump">13,342,679<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>15 <FILENAME>R5.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834729232"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Jun. 30, 2022</div></th> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Jun. 30, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td> <td class="nump">$ 0.03<span></span> </td> <td class="nump">$ 0.05<span></span> </td> <td class="nump">$ 0.04<span></span> </td> <td class="nump">$ 0.06<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares used in computing diluted net loss per share (in Shares)</a></td> <td class="nump">16,109,514<span></span> </td> <td class="nump">13,647,151<span></span> </td> <td class="nump">16,037,214<span></span> </td> <td class="nump">13,342,679<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>16 <FILENAME>R6.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542833436368"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>Common stock</div></th> <th class="th"><div>Additional paid-in capital</div></th> <th class="th"><div>Accumulated deficit</div></th> <th class="th"><div>Total</div></th> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td> <td class="nump">$ 130<span></span> </td> <td class="nump">$ 2,665<span></span> </td> <td class="num">$ (2,667)<span></span> </td> <td class="nump">$ 128<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td> <td class="nump">12,970,540<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td> <td class="nump">$ 3<span></span> </td> <td class="nump">157<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">161<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (in Shares)</a></td> <td class="nump">320,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(185)<span></span> </td> <td class="num">(185)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td> <td class="nump">$ 133<span></span> </td> <td class="nump">2,822<span></span> </td> <td class="num">(2,852)<span></span> </td> <td class="nump">103<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td> <td class="nump">13,290,540<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td> <td class="nump">$ 130<span></span> </td> <td class="nump">2,665<span></span> </td> <td class="num">(2,667)<span></span> </td> <td class="nump">128<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td> <td class="nump">12,970,540<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(812)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td> <td class="nump">$ 143<span></span> </td> <td class="nump">3,454<span></span> </td> <td class="num">(3,479)<span></span> </td> <td class="nump">118<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td> <td class="nump">14,225,540<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td> <td class="nump">$ 133<span></span> </td> <td class="nump">2,822<span></span> </td> <td class="num">(2,852)<span></span> </td> <td class="nump">103<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td> <td class="nump">13,290,540<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td> <td class="nump">$ 7<span></span> </td> <td class="nump">345<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">352<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (in Shares)</a></td> <td class="nump">655,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in exchange for services</a></td> <td class="nump">$ 3<span></span> </td> <td class="nump">287<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">290<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in exchange for services (in Shares)</a></td> <td class="nump">280,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(627)<span></span> </td> <td class="num">(627)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td> <td class="nump">$ 143<span></span> </td> <td class="nump">3,454<span></span> </td> <td class="num">(3,479)<span></span> </td> <td class="nump">118<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td> <td class="nump">14,225,540<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td> <td class="nump">$ 157<span></span> </td> <td class="nump">5,975<span></span> </td> <td class="num">(6,026)<span></span> </td> <td class="nump">106<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td> <td class="nump">15,624,040<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td> <td class="nump">$ 3<span></span> </td> <td class="nump">146<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">149<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (in Shares)</a></td> <td class="nump">378,750<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(264)<span></span> </td> <td class="num">(264)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td> <td class="nump">$ 160<span></span> </td> <td class="nump">6,121<span></span> </td> <td class="num">(6,290)<span></span> </td> <td class="num">(9)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td> <td class="nump">16,002,790<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td> <td class="nump">$ 157<span></span> </td> <td class="nump">5,975<span></span> </td> <td class="num">(6,026)<span></span> </td> <td class="nump">106<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td> <td class="nump">15,624,040<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(681)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td> <td class="nump">$ 164<span></span> </td> <td class="nump">6,482<span></span> </td> <td class="num">(6,707)<span></span> </td> <td class="num">(61)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td> <td class="nump">16,368,168<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td> <td class="nump">$ 160<span></span> </td> <td class="nump">6,121<span></span> </td> <td class="num">(6,290)<span></span> </td> <td class="num">(9)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td> <td class="nump">16,002,790<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td> <td class="nump">$ 2<span></span> </td> <td class="nump">163<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">165<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (in Shares)</a></td> <td class="nump">164,378<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in exchange for services</a></td> <td class="nump">$ 2<span></span> </td> <td class="nump">198<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">200<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in exchange for services (in Shares)</a></td> <td class="nump">201,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(417)<span></span> </td> <td class="num">(417)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td> <td class="nump">$ 164<span></span> </td> <td class="nump">$ 6,482<span></span> </td> <td class="num">$ (6,707)<span></span> </td> <td class="num">$ (61)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td> <td class="nump">16,368,168<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>17 <FILENAME>R7.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834816272"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Jun. 30, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td> <td class="num">$ (681)<span></span> </td> <td class="num">$ (812)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payment in exchange for services</a></td> <td class="nump">200<span></span> </td> <td class="nump">290<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td> <td class="nump">1<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td> <td class="nump">36<span></span> </td> <td class="nump">258<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Account payables and related party</a></td> <td class="num">(170)<span></span> </td> <td class="num">(66)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td> <td class="num">(614)<span></span> </td> <td class="num">(330)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock and warrants</a></td> <td class="nump">314<span></span> </td> <td class="nump">312<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_AdvancePaymentOnAccountOfShares', window );">Advance payment on account of shares</a></td> <td class="nump">123<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td> <td class="nump">437<span></span> </td> <td class="nump">312<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td> <td class="num">(177)<span></span> </td> <td class="num">(18)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the beginning of the period</a></td> <td class="nump">288<span></span> </td> <td class="nump">153<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the end of the period</a></td> <td class="nump">$ 111<span></span> </td> <td class="nump">$ 135<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_AdvancePaymentOnAccountOfShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payment on account of shares.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_AdvancePaymentOnAccountOfShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Depreciation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProfitLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>18 <FILENAME>R8.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834830208"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td> <td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE</b></span> <b>1:-</b></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> GENERAL</b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Raphael Pharmaceutical Inc. (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, Raphael and the Company completed the Share Exchange pursuant to which 9,459,253 shares of common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding shares of common stock of the Company immediately after the Share Exchange while the Company’s shareholders held, following the Share Exchange, 1,051,028 shares of common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company’s common stock began public trading on the over-the-counter market in the U.S. in January 2023 under the symbol “RAPH”.</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going concern and management plans</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of June 30, 2023, the Company’s accumulated deficit was $6,706. The Company has funded its operations to date primarily through equity financing and the issuance of a loan.  Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>19 <FILENAME>R9.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542839766752"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td> <td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> NOTE 2:- </b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2022. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2022, are applied consistently in these interim financial statements.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>20 <FILENAME>R10.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542839681344"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Interim Financial Statements<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Unaudited Interim Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsTextBlock', window );">UNAUDITED INTERIM FINANCIAL STATEMENTS</a></td> <td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED INTERIM FINANCIAL STATEMENTS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Operating results for the six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>srt_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial statements.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_CondensedFinancialStatementsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>srt_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>21 <FILENAME>R11.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542838362496"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders’ Equity<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders’ Equity [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS’ EQUITY</a></td> <td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHAREHOLDERS’ EQUITY </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company issued 255,750 shares of common stock following certain share purchase agreements dated November and December 2022.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2022, the Company signed an agreement to raise $7.5 and to issue 6,000 shares of common stock and 18,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investor of the Company. The warrants are exercisable until February 28, 2024. The investment above and share issuance took place in January 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2023, certain investor of the Company and the Company signed an agreement to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share following the exercise of an option for additional investment. The warrants are exercisable until April 30, 2024. In January 2023, the investor and the Company agreed on $117 out of the $250 investment. As a result, the Company received $117 and issued 117,000 shares of common stock and the issuance of 100,000 warrants to purchase common stock of the Company were cancelled.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From March through June, 2023, certain investors of the Company and the Company signed an agreement to raise $190 and to issue 164,378 shares of common stock. The shares were issued in April 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2023, certain investor of the Company and the Company signed an agreement to exercise investors warrants into Company’s common stock. In May 2023, the investor transferred $123. As of June 30, 2023 the stock weren’t issued yet and as such, investors’ funds were recorded as an advance on account of shares.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, the Company issued 201,000 shares of common stock to Way of Life Cannabis Ltd., or Wolc, in connection with the services agreement dated October 2020. The value of the shares issued was based on the value of the service provided and amounted to $200.</span></td></tr> </table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>22 <FILENAME>R12.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542834894160"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>May 14, 2021</div></th> <th class="th"><div>Oct. 08, 2020</div></th> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Dec. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_IssuedAndOutstandingShareCapitalPercentage', window );">Issued and outstanding share capital percentage</a></td> <td class="nump">90.00%<span></span> </td> <td class="nump">90.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_CommonStockPercentage', window );">Common stock percentage</a></td> <td class="nump">10.00%<span></span> </td> <td class="nump">10.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td> <td class="nump">100<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">16,368,168<span></span> </td> <td class="nump">15,624,040<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td> <td class="nump">100<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">16,368,168<span></span> </td> <td class="nump">15,624,040<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued</a></td> <td class="nump">9,459,253<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share exchange common stock</a></td> <td class="nump">1,051,028<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsUnappropriated', window );">Accumulated deficit</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 6,706<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_CommonStockPercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock percentage.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_CommonStockPercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_IssuedAndOutstandingShareCapitalPercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and Outstanding Share Capital percentage.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_IssuedAndOutstandingShareCapitalPercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsUnappropriated"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsUnappropriated</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>23 <FILENAME>R13.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140542838512064"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders’ Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1">1 Months Ended</th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Jun. 30, 2023</div></th> <th class="th"><div>Jan. 31, 2023</div></th> <th class="th"><div>Jan. 08, 2023</div></th> <th class="th"><div>Dec. 30, 2022</div></th> <th class="th"><div>May 31, 2023</div></th> <th class="th"><div>Dec. 31, 2022</div></th> <th class="th"><div>May 14, 2021</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders’ Equity (Details) [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares issued</a></td> <td class="nump">201,000<span></span> </td> <td class="nump">255,750<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price per share (in Dollars per share)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.13<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_CompanyRaisedAmount', window );">Company raised amount (in Dollars)</a></td> <td class="nump">$ 190<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td> <td class="nump">16,368,168<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">15,624,040<span></span> </td> <td class="nump">100<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Agreed amount (in Dollars)</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 117<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Investment amount (in Dollars)</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 250<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferToInvestments', window );">Investor transferred (in Dollars)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 123<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Service provided (in Dollars)</a></td> <td class="nump">$ 200<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders’ Equity (Details) [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_PurchaseWarrants', window );">Warrants purchase</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">100,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_CompanyRaisedAmount', window );">Company raised amount (in Dollars)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 250<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">250,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders’ Equity (Details) [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares issued</a></td> <td class="nump">164,378<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">6,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_CompanyRaisedPricePerShare', window );">Company raised price per share (in Dollars per share)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 7.5<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_raph_PurchaseWarrants', window );">Warrants purchase</a></td> <td class="text"> <span></span> </td> <td class="nump">100,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">18,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price per share (in Dollars per share)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.25<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td> <td class="text"> <span></span> </td> <td class="nump">117,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherValueOutstanding', window );">Amount received (in Dollars)</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 117<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_CompanyRaisedAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company raised amount.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_CompanyRaisedAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_CompanyRaisedPricePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company raised price per share.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_CompanyRaisedPricePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_PurchaseWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of purchase warrants.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_PurchaseWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_raph_ShareholdersEquityDetailsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">raph_ShareholdersEquityDetailsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>raph_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherValueOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockOtherValueOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferToInvestments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of investments transferred to the entity's investments in noncash transactions.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TransferToInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>24 <FILENAME>f10q0623_raphaelpharma_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version="1.0" encoding="utf-8"?> <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:raph="http://www.raphaelpharmaceutical.com/20230630" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:schemaRef xlink:href="raph-20230630.xsd" xlink:type="simple"/> <context id="c0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2023-01-01</startDate> <endDate>2023-06-30</endDate> </period> </context> <context id="c1"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2023-08-09</instant> </period> </context> <context id="c2"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2023-06-30</instant> </period> </context> <context id="c3"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2022-12-31</instant> </period> </context> <context id="c4"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2022-01-01</startDate> <endDate>2022-06-30</endDate> </period> </context> <context id="c5"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2023-04-01</startDate> <endDate>2023-06-30</endDate> </period> </context> <context id="c6"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2022-04-01</startDate> <endDate>2022-06-30</endDate> </period> </context> <context id="c7"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-12-31</instant> </period> </context> <context id="c8"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-12-31</instant> </period> </context> <context id="c9"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-12-31</instant> </period> </context> <context id="c10"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-01-01</startDate> <endDate>2023-03-31</endDate> </period> </context> <context id="c11"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-01-01</startDate> <endDate>2023-03-31</endDate> </period> </context> <context id="c12"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-01-01</startDate> <endDate>2023-03-31</endDate> </period> </context> <context id="c13"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2023-01-01</startDate> <endDate>2023-03-31</endDate> </period> </context> <context id="c14"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-03-31</instant> </period> </context> <context id="c15"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-03-31</instant> </period> </context> <context id="c16"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-03-31</instant> </period> </context> <context id="c17"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2023-03-31</instant> </period> </context> <context id="c18"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-04-01</startDate> <endDate>2023-06-30</endDate> </period> </context> <context id="c19"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-04-01</startDate> <endDate>2023-06-30</endDate> </period> </context> <context id="c20"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-04-01</startDate> <endDate>2023-06-30</endDate> </period> </context> <context id="c21"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-06-30</instant> </period> </context> <context id="c22"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-06-30</instant> </period> </context> <context id="c23"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-06-30</instant> </period> </context> <context id="c24"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-12-31</instant> </period> </context> <context id="c25"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-12-31</instant> </period> </context> <context id="c26"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-12-31</instant> </period> </context> <context id="c27"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2021-12-31</instant> </period> </context> <context id="c28"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-01-01</startDate> <endDate>2022-03-31</endDate> </period> </context> <context id="c29"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-01-01</startDate> <endDate>2022-03-31</endDate> </period> </context> <context id="c30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-01-01</startDate> <endDate>2022-03-31</endDate> </period> </context> <context id="c31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2022-01-01</startDate> <endDate>2022-03-31</endDate> </period> </context> <context id="c32"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-03-31</instant> </period> </context> <context id="c33"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-03-31</instant> </period> </context> <context id="c34"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-03-31</instant> </period> </context> <context id="c35"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2022-03-31</instant> </period> </context> <context id="c36"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-04-01</startDate> <endDate>2022-06-30</endDate> </period> </context> <context id="c37"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-04-01</startDate> <endDate>2022-06-30</endDate> </period> </context> <context id="c38"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-04-01</startDate> <endDate>2022-06-30</endDate> </period> </context> <context id="c39"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-06-30</instant> </period> </context> <context id="c40"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-06-30</instant> </period> </context> <context id="c41"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-06-30</instant> </period> </context> <context id="c42"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2022-06-30</instant> </period> </context> <context id="c43"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2020-10-08</startDate> <endDate>2020-10-08</endDate> </period> </context> <context id="c44"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2021-05-14</instant> </period> </context> <context id="c45"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2021-05-14</startDate> <endDate>2021-05-14</endDate> </period> </context> <context id="c46"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2023-01-31</instant> </period> </context> <context id="c47"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-12-30</startDate> <endDate>2022-12-30</endDate> </period> </context> <context id="c48"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-12-30</instant> </period> </context> <context id="c49"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-01-08</startDate> <endDate>2023-01-08</endDate> </period> </context> <context id="c50"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-01-08</instant> </period> </context> <context id="c51"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <instant>2023-01-08</instant> </period> </context> <context id="c52"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-01-31</instant> </period> </context> <context id="c53"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-01-31</startDate> <endDate>2023-01-31</endDate> </period> </context> <context id="c54"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2023-06-30</startDate> <endDate>2023-06-30</endDate> </period> </context> <context id="c55"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001415397</identifier> </entity> <period> <startDate>2023-05-01</startDate> <endDate>2023-05-31</endDate> </period> </context> <unit id="shares"> <measure>shares</measure> </unit> <unit id="usd"> <measure>iso4217:USD</measure> </unit> <unit id="usdPershares"> <divide> <unitNumerator> <measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>shares</measure> </unitDenominator> </divide> </unit> <unit id="pure"> <measure>pure</measure> </unit> <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType> <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport> <dei:DocumentPeriodEndDate contextRef="c0">2023-06-30</dei:DocumentPeriodEndDate> <dei:DocumentFiscalYearFocus contextRef="c0">2023</dei:DocumentFiscalYearFocus> <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport> <dei:EntityFileNumber contextRef="c0">000-53002</dei:EntityFileNumber> <dei:EntityRegistrantName contextRef="c0">Raphael Pharmaceutical Inc.</dei:EntityRegistrantName> <dei:EntityIncorporationStateCountryCode contextRef="c0">NV</dei:EntityIncorporationStateCountryCode> <dei:EntityTaxIdentificationNumber contextRef="c0">26-0204284</dei:EntityTaxIdentificationNumber> <dei:EntityAddressAddressLine1 contextRef="c0">4 Lui Paster Street</dei:EntityAddressAddressLine1> <dei:EntityAddressCityOrTown contextRef="c0">Tel Aviv-Jaffa</dei:EntityAddressCityOrTown> <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry> <dei:EntityAddressPostalZipCode contextRef="c0">6803605</dei:EntityAddressPostalZipCode> <dei:CityAreaCode contextRef="c0">(+972)</dei:CityAreaCode> <dei:LocalPhoneNumber contextRef="c0">52-775-5072</dei:LocalPhoneNumber> <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus> <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent> <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory> <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness> <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany> <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany> <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">16368168</dei:EntityCommonStockSharesOutstanding> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">111000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">288000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">7000</us-gaap:OtherAssetsCurrent> <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">43000</us-gaap:OtherAssetsCurrent> <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">118000</us-gaap:AssetsCurrent> <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">331000</us-gaap:AssetsCurrent> <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="-3" unitRef="usd">1000</us-gaap:FiniteLivedIntangibleAssetsNet> <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="-3" unitRef="usd">2000</us-gaap:FiniteLivedIntangibleAssetsNet> <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">119000</us-gaap:Assets> <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">333000</us-gaap:Assets> <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">141000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent> <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">224000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent> <us-gaap:NotesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">39000</us-gaap:NotesPayableCurrent> <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">3000</us-gaap:NotesPayableCurrent> <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">180000</us-gaap:LiabilitiesCurrent> <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">227000</us-gaap:LiabilitiesCurrent> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="2" unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="2" unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">21020560</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">21020560</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">16368168</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">16368168</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">15624040</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">15624040</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">164000</us-gaap:CommonStockValue> <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">157000</us-gaap:CommonStockValue> <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">6482000</us-gaap:AdditionalPaidInCapital> <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">5975000</us-gaap:AdditionalPaidInCapital> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-6707000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-6026000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">-61000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">106000</us-gaap:StockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">119000</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">333000</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">407000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">170000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">293000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" unitRef="usd">84000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">270000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">617000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">126000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" unitRef="usd">528000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-677000</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-787000</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-419000</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-612000</us-gaap:OperatingIncomeLoss> <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-4000</us-gaap:NonoperatingIncomeExpense> <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">-25000</us-gaap:NonoperatingIncomeExpense> <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">2000</us-gaap:NonoperatingIncomeExpense> <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" unitRef="usd">-15000</us-gaap:NonoperatingIncomeExpense> <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-681000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-812000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-417000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-627000</us-gaap:NetIncomeLoss> <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">0.04</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">0.06</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">0.03</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic contextRef="c6" decimals="2" unitRef="usdPershares">0.05</us-gaap:EarningsPerShareBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">16037214</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="INF" unitRef="shares">13342679</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="INF" unitRef="shares">16109514</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c6" decimals="INF" unitRef="shares">13647151</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:SharesOutstanding contextRef="c7" decimals="INF" unitRef="shares">15624040</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">157000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" unitRef="usd">5975000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">-6026000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">106000</us-gaap:StockholdersEquity> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c10" decimals="INF" unitRef="shares">378750</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c10" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="-3" unitRef="usd">146000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="-3" unitRef="usd">149000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">-264000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" unitRef="usd">-264000</us-gaap:NetIncomeLoss> <us-gaap:SharesOutstanding contextRef="c14" decimals="INF" unitRef="shares">16002790</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" unitRef="usd">160000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" unitRef="usd">6121000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">-6290000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">-9000</us-gaap:StockholdersEquity> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c18" decimals="INF" unitRef="shares">164378</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c18" decimals="-3" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c19" decimals="-3" unitRef="usd">163000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" unitRef="usd">165000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c18" decimals="INF" unitRef="shares">201000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c18" decimals="-3" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c19" decimals="-3" unitRef="usd">198000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="-3" unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices> <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" unitRef="usd">-417000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-417000</us-gaap:NetIncomeLoss> <us-gaap:SharesOutstanding contextRef="c21" decimals="INF" unitRef="shares">16368168</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" unitRef="usd">164000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" unitRef="usd">6482000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" unitRef="usd">-6707000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">-61000</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="c24" decimals="INF" unitRef="shares">12970540</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" unitRef="usd">130000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">2665000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" unitRef="usd">-2667000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">128000</us-gaap:StockholdersEquity> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c28" decimals="INF" unitRef="shares">320000</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c28" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="-3" unitRef="usd">157000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c31" decimals="-3" unitRef="usd">161000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" unitRef="usd">-185000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" unitRef="usd">-185000</us-gaap:NetIncomeLoss> <us-gaap:SharesOutstanding contextRef="c32" decimals="INF" unitRef="shares">13290540</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">133000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">2822000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" unitRef="usd">-2852000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" unitRef="usd">103000</us-gaap:StockholdersEquity> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c36" decimals="INF" unitRef="shares">655000</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="-3" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c37" decimals="-3" unitRef="usd">345000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c6" decimals="-3" unitRef="usd">352000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c36" decimals="INF" unitRef="shares">280000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c36" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c37" decimals="-3" unitRef="usd">287000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c6" decimals="-3" unitRef="usd">290000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices> <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" unitRef="usd">-627000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-627000</us-gaap:NetIncomeLoss> <us-gaap:SharesOutstanding contextRef="c39" decimals="INF" unitRef="shares">14225540</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" unitRef="usd">143000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" unitRef="usd">3454000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" unitRef="usd">-3479000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" unitRef="usd">118000</us-gaap:StockholdersEquity> <us-gaap:ProfitLoss contextRef="c0" decimals="-3" unitRef="usd">-681000</us-gaap:ProfitLoss> <us-gaap:ProfitLoss contextRef="c4" decimals="-3" unitRef="usd">-812000</us-gaap:ProfitLoss> <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">200000</us-gaap:ShareBasedCompensation> <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">290000</us-gaap:ShareBasedCompensation> <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:Depreciation> <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" unitRef="usd">-36000</us-gaap:IncreaseDecreaseInOtherCurrentAssets> <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c4" decimals="-3" unitRef="usd">-258000</us-gaap:IncreaseDecreaseInOtherCurrentAssets> <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c0" decimals="-3" unitRef="usd">-170000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties> <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c4" decimals="-3" unitRef="usd">-66000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-614000</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-330000</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" unitRef="usd">314000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c4" decimals="-3" unitRef="usd">312000</us-gaap:ProceedsFromIssuanceOfCommonStock> <raph:AdvancePaymentOnAccountOfShares contextRef="c0" decimals="-3" unitRef="usd">123000</raph:AdvancePaymentOnAccountOfShares> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">437000</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">312000</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">-18000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c27" decimals="-3" unitRef="usd">153000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c42" decimals="-3" unitRef="usd">135000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations> <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE</b></span> <b>1:-</b></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> GENERAL</b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Raphael Pharmaceutical Inc. (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, Raphael and the Company completed the Share Exchange pursuant to which 9,459,253 shares of common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding shares of common stock of the Company immediately after the Share Exchange while the Company’s shareholders held, following the Share Exchange, 1,051,028 shares of common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company’s common stock began public trading on the over-the-counter market in the U.S. in January 2023 under the symbol “RAPH”.</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going concern and management plans</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of June 30, 2023, the Company’s accumulated deficit was $6,706. The Company has funded its operations to date primarily through equity financing and the issuance of a loan.  Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</p></us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock> <raph:IssuedAndOutstandingShareCapitalPercentage contextRef="c43" decimals="2" unitRef="pure">0.90</raph:IssuedAndOutstandingShareCapitalPercentage> <raph:CommonStockPercentage contextRef="c43" decimals="2" unitRef="pure">0.10</raph:CommonStockPercentage> <us-gaap:CommonStockSharesIssued contextRef="c44" decimals="0" unitRef="shares">100</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="c44" decimals="0" unitRef="shares">100</us-gaap:CommonStockSharesOutstanding> <us-gaap:ConversionOfStockSharesIssued1 contextRef="c45" decimals="0" unitRef="shares">9459253</us-gaap:ConversionOfStockSharesIssued1> <raph:IssuedAndOutstandingShareCapitalPercentage contextRef="c45" decimals="2" unitRef="pure">0.90</raph:IssuedAndOutstandingShareCapitalPercentage> <us-gaap:SharesIssued contextRef="c44" decimals="0" unitRef="shares">1051028</us-gaap:SharesIssued> <raph:CommonStockPercentage contextRef="c45" decimals="2" unitRef="pure">0.10</raph:CommonStockPercentage> <us-gaap:RetainedEarningsUnappropriated contextRef="c2" decimals="-3" unitRef="usd">6706000</us-gaap:RetainedEarningsUnappropriated> <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> NOTE 2:- </b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2022. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2022, are applied consistently in these interim financial statements.</p></us-gaap:SignificantAccountingPoliciesTextBlock> <srt:CondensedFinancialStatementsTextBlock contextRef="c0"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED INTERIM FINANCIAL STATEMENTS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Operating results for the six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</p></srt:CondensedFinancialStatementsTextBlock> <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHAREHOLDERS’ EQUITY </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company issued 255,750 shares of common stock following certain share purchase agreements dated November and December 2022.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2022, the Company signed an agreement to raise $7.5 and to issue 6,000 shares of common stock and 18,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investor of the Company. The warrants are exercisable until February 28, 2024. The investment above and share issuance took place in January 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2023, certain investor of the Company and the Company signed an agreement to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share following the exercise of an option for additional investment. The warrants are exercisable until April 30, 2024. In January 2023, the investor and the Company agreed on $117 out of the $250 investment. As a result, the Company received $117 and issued 117,000 shares of common stock and the issuance of 100,000 warrants to purchase common stock of the Company were cancelled.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From March through June, 2023, certain investors of the Company and the Company signed an agreement to raise $190 and to issue 164,378 shares of common stock. The shares were issued in April 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2023, certain investor of the Company and the Company signed an agreement to exercise investors warrants into Company’s common stock. In May 2023, the investor transferred $123. As of June 30, 2023 the stock weren’t issued yet and as such, investors’ funds were recorded as an advance on account of shares.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, the Company issued 201,000 shares of common stock to Way of Life Cannabis Ltd., or Wolc, in connection with the services agreement dated October 2020. The value of the shares issued was based on the value of the service provided and amounted to $200.</span></td></tr> </table></us-gaap:StockholdersEquityNoteDisclosureTextBlock> <us-gaap:ExcessStockSharesIssued contextRef="c46" decimals="0" unitRef="shares">255750</us-gaap:ExcessStockSharesIssued> <raph:CompanyRaisedPricePerShare contextRef="c47" decimals="1" unitRef="usdPershares">7.5</raph:CompanyRaisedPricePerShare> <us-gaap:ExcessStockSharesIssued contextRef="c48" decimals="0" unitRef="shares">6000</us-gaap:ExcessStockSharesIssued> <raph:PurchaseWarrants contextRef="c47" decimals="0" unitRef="shares">18000</raph:PurchaseWarrants> <us-gaap:SharesIssuedPricePerShare contextRef="c48" decimals="2" unitRef="usdPershares">1.25</us-gaap:SharesIssuedPricePerShare> <raph:CompanyRaisedAmount contextRef="c49" decimals="-3" unitRef="usd">250000</raph:CompanyRaisedAmount> <us-gaap:CommonStockSharesIssued contextRef="c50" decimals="0" unitRef="shares">250000</us-gaap:CommonStockSharesIssued> <raph:PurchaseWarrants contextRef="c49" decimals="0" unitRef="shares">100000</raph:PurchaseWarrants> <us-gaap:SharesIssuedPricePerShare contextRef="c51" decimals="2" unitRef="usdPershares">1.13</us-gaap:SharesIssuedPricePerShare> <us-gaap:EquityMethodInvestmentAggregateCost contextRef="c46" decimals="-3" unitRef="usd">117000</us-gaap:EquityMethodInvestmentAggregateCost> <us-gaap:EquityMethodInvestmentQuotedMarketValue contextRef="c46" decimals="-3" unitRef="usd">250000</us-gaap:EquityMethodInvestmentQuotedMarketValue> <us-gaap:CommonStockOtherValueOutstanding contextRef="c52" decimals="-3" unitRef="usd">117000</us-gaap:CommonStockOtherValueOutstanding> <us-gaap:CommonStockSharesIssued contextRef="c52" decimals="0" unitRef="shares">117000</us-gaap:CommonStockSharesIssued> <raph:PurchaseWarrants contextRef="c53" decimals="0" unitRef="shares">100000</raph:PurchaseWarrants> <raph:CompanyRaisedAmount contextRef="c54" decimals="-3" unitRef="usd">190000</raph:CompanyRaisedAmount> <us-gaap:ExcessStockSharesIssued contextRef="c21" decimals="0" unitRef="shares">164378</us-gaap:ExcessStockSharesIssued> <us-gaap:TransferToInvestments contextRef="c55" decimals="-3" unitRef="usd">123000</us-gaap:TransferToInvestments> <us-gaap:ExcessStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">201000</us-gaap:ExcessStockSharesIssued> <us-gaap:OtherCostAndExpenseOperating contextRef="c54" decimals="-3" unitRef="usd">200000</us-gaap:OtherCostAndExpenseOperating> <us-gaap:EarningsPerShareDiluted contextRef="c5" decimals="2" id="hidden-fact-0" unitRef="usdPershares">0.03</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareDiluted contextRef="c0" decimals="2" id="hidden-fact-1" unitRef="usdPershares">0.04</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareDiluted contextRef="c6" decimals="2" id="hidden-fact-2" unitRef="usdPershares">0.05</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareDiluted contextRef="c4" decimals="2" id="hidden-fact-3" unitRef="usdPershares">0.06</us-gaap:EarningsPerShareDiluted> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c4" decimals="INF" id="hidden-fact-4" unitRef="shares">13342679</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c6" decimals="INF" id="hidden-fact-5" unitRef="shares">13647151</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="INF" id="hidden-fact-6" unitRef="shares">16037214</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c5" decimals="INF" id="hidden-fact-7" unitRef="shares">16109514</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" id="hidden-fact-8" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c10" id="hidden-fact-9" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c11" id="hidden-fact-10" unitRef="usd" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20" id="hidden-fact-11" unitRef="usd" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20" id="hidden-fact-12" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c18" id="hidden-fact-13" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c19" id="hidden-fact-14" unitRef="usd" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c30" id="hidden-fact-15" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c28" id="hidden-fact-16" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c29" id="hidden-fact-17" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c36" id="hidden-fact-18" unitRef="usd" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="c37" id="hidden-fact-19" unitRef="usd" xsi:nil="true"/> <us-gaap:Depreciation contextRef="c4" id="hidden-fact-20" unitRef="usd" xsi:nil="true"/> <raph:AdvancePaymentOnAccountOfShares contextRef="c4" id="hidden-fact-21" unitRef="usd" xsi:nil="true"/> <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag> <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate> <dei:DocumentFiscalPeriodFocus contextRef="c0">Q2</dei:DocumentFiscalPeriodFocus> <dei:EntityCentralIndexKey contextRef="c0">0001415397</dei:EntityCentralIndexKey> </xbrl> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>25 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xlsx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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>26 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>27 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>28 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version='1.0' encoding='utf-8'?> <FilingSummary> <Version>3.23.2</Version> <ProcessingTime/> <ReportFormat>html</ReportFormat> <ContextCount>56</ContextCount> <ElementCount>87</ElementCount> <EntityCount>1</EntityCount> <FootnotesReported>false</FootnotesReported> <SegmentCount>4</SegmentCount> <ScenarioCount>0</ScenarioCount> <TuplesReported>false</TuplesReported> <UnitCount>4</UnitCount> <MyReports> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R1.htm</HtmlFileName> <LongName>000 - Document - Document And Entity Information</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation</Role> <ShortName>Document And Entity Information</ShortName> <MenuCategory>Cover</MenuCategory> <Position>1</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R2.htm</HtmlFileName> <LongName>001 - Statement - Condensed Consolidated Interim Balance Sheets</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet</Role> <ShortName>Condensed Consolidated Interim Balance Sheets</ShortName> <MenuCategory>Statements</MenuCategory> <Position>2</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R3.htm</HtmlFileName> <LongName>002 - Statement - Condensed Consolidated Interim Balance Sheets (Parentheticals)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals</Role> <ShortName>Condensed Consolidated Interim Balance Sheets (Parentheticals)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>3</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R4.htm</HtmlFileName> <LongName>003 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement</Role> <ShortName>Condensed Consolidated Interim Statements of Comprehensive Loss</ShortName> <MenuCategory>Statements</MenuCategory> <Position>4</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R5.htm</HtmlFileName> <LongName>004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss (Parentheticals)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals</Role> <ShortName>Condensed Consolidated Interim Statements of Comprehensive Loss (Parentheticals)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>5</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R6.htm</HtmlFileName> <LongName>005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders??? Equity (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3</Role> <ShortName>Condensed Consolidated Interim Statements of Changes in Stockholders??? Equity (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>6</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R7.htm</HtmlFileName> <LongName>006 - Statement - Condensed Consolidated Interim Statements of Cash Flows</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow</Role> <ShortName>Condensed Consolidated Interim Statements of Cash Flows</ShortName> <MenuCategory>Statements</MenuCategory> <Position>7</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R8.htm</HtmlFileName> <LongName>007 - Disclosure - General</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/General</Role> <ShortName>General</ShortName> <MenuCategory>Notes</MenuCategory> <Position>8</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R9.htm</HtmlFileName> <LongName>008 - Disclosure - Significant Accounting Policies</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies</Role> <ShortName>Significant Accounting Policies</ShortName> <MenuCategory>Notes</MenuCategory> <Position>9</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R10.htm</HtmlFileName> <LongName>009 - Disclosure - Unaudited Interim Financial Statements</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements</Role> <ShortName>Unaudited Interim Financial Statements</ShortName> <MenuCategory>Notes</MenuCategory> <Position>10</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R11.htm</HtmlFileName> <LongName>010 - Disclosure - Shareholders??? Equity</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ShareholdersEquity</Role> <ShortName>Shareholders??? Equity</ShortName> <MenuCategory>Notes</MenuCategory> <Position>11</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R12.htm</HtmlFileName> <LongName>011 - Disclosure - General (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/GeneralDetails</Role> <ShortName>General (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.raphaelpharmaceutical.com/role/General</ParentRole> <Position>12</Position> </Report> <Report instance="f10q0623_raphaelpharma.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R13.htm</HtmlFileName> <LongName>012 - Disclosure - Shareholders??? Equity (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails</Role> <ShortName>Shareholders??? Equity (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.raphaelpharmaceutical.com/role/ShareholdersEquity</ParentRole> <Position>13</Position> </Report> <Report> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <LongName>All Reports</LongName> <ReportType>Book</ReportType> <ShortName>All Reports</ShortName> </Report> </MyReports> <Logs> <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0623_raphaelpharma.htm 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997</Log> </Logs> <InputFiles> <File doctype="10-Q" original="f10q0623_raphaelpharma.htm">f10q0623_raphaelpharma.htm</File> <File>f10q0623ex31-1_raphael.htm</File> <File>f10q0623ex31-2_raphael.htm</File> <File>f10q0623ex32-1_raphael.htm</File> <File>f10q0623ex32-2_raphael.htm</File> <File>raph-20230630.xsd</File> <File>raph-20230630_cal.xml</File> <File>raph-20230630_def.xml</File> <File>raph-20230630_lab.xml</File> <File>raph-20230630_pre.xml</File> </InputFiles> <SupplementalFiles/> <BaseTaxonomies> <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy> <BaseTaxonomy items="187">http://fasb.org/us-gaap/2023</BaseTaxonomy> <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy> </BaseTaxonomies> <HasPresentationLinkbase>true</HasPresentationLinkbase> <HasCalculationLinkbase>true</HasCalculationLinkbase> </FilingSummary> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>31 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> { "instance": { "f10q0623_raphaelpharma.htm": { "axisCustom": 0, "axisStandard": 2, "baseTaxonomies": { "http://fasb.org/srt/2023": 1, "http://fasb.org/us-gaap/2023": 187, "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 56, "dts": { "calculationLink": { "local": [ "raph-20230630_cal.xml" ] }, "definitionLink": { "local": [ "raph-20230630_def.xml" ] }, "inline": { "local": [ "f10q0623_raphaelpharma.htm" ] }, "labelLink": { "local": [ "raph-20230630_lab.xml" ] }, "presentationLink": { "local": [ "raph-20230630_pre.xml" ] }, "schema": { "local": [ "raph-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 117, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 21, "http://www.raphaelpharmaceutical.com/20230630": 1, "http://xbrl.sec.gov/dei/2023": 4, "total": 26 }, "keyCustom": 6, "keyStandard": 81, "memberCustom": 0, "memberStandard": 4, "nsprefix": "raph", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:CondensedFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Unaudited Interim Financial Statements", "menuCat": "Notes", "order": "10", "role": "http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements", "shortName": "Unaudited Interim Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:CondensedFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Shareholders\u2019 Equity", "menuCat": "Notes", "order": "11", "role": "http://www.raphaelpharmaceutical.com/role/ShareholdersEquity", "shortName": "Shareholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c45", "decimals": "2", "first": true, "lang": null, "name": "raph:IssuedAndOutstandingShareCapitalPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - General (Details)", "menuCat": "Details", "order": "12", "role": "http://www.raphaelpharmaceutical.com/role/GeneralDetails", "shortName": "General (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c45", "decimals": "2", "first": true, "lang": null, "name": "raph:IssuedAndOutstandingShareCapitalPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Shareholders\u2019 Equity (Details)", "menuCat": "Details", "order": "13", "role": "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails", "shortName": "Shareholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Interim Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Interim Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c2", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Interim Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Interim Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c2", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Interim Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Interim Statements of Comprehensive Loss (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c24", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Interim Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c28", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Interim Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Interim Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - General", "menuCat": "Notes", "order": "8", "role": "http://www.raphaelpharmaceutical.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0623_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "raph_AdvancePaymentOnAccountOfShares": { "auth_ref": [], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advance payment on account of shares.", "label": "Advance Payment On Account Of Shares", "terseLabel": "Advance payment on account of shares" } } }, "localname": "AdvancePaymentOnAccountOfShares", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "raph_CommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock percentage.", "label": "Common Stock Percentage", "terseLabel": "Common stock percentage" } } }, "localname": "CommonStockPercentage", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/GeneralDetails" ], "xbrltype": "percentItemType" }, "raph_CompanyRaisedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Company raised amount.", "label": "Company Raised Amount", "terseLabel": "Company raised amount (in Dollars)" } } }, "localname": "CompanyRaisedAmount", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "raph_CompanyRaisedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company raised price per share.", "label": "Company Raised Price Per Share", "terseLabel": "Company raised price per share (in Dollars per share)" } } }, "localname": "CompanyRaisedPricePerShare", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "raph_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "xbrltype": "stringItemType" }, "raph_IssuedAndOutstandingShareCapitalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and Outstanding Share Capital percentage.", "label": "Issued And Outstanding Share Capital Percentage", "terseLabel": "Issued and outstanding share capital percentage" } } }, "localname": "IssuedAndOutstandingShareCapitalPercentage", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/GeneralDetails" ], "xbrltype": "percentItemType" }, "raph_PurchaseWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The value of purchase warrants.", "label": "Purchase Warrants", "terseLabel": "Warrants purchase" } } }, "localname": "PurchaseWarrants", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "raph_ShareholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Details) [Line Items]" } } }, "localname": "ShareholdersEquityDetailsLineItems", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "raph_ShareholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Details) [Table]" } } }, "localname": "ShareholdersEquityDetailsTable", "nsuri": "http://www.raphaelpharmaceutical.com/20230630", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unaudited Interim Financial Statements [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2023", "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsTextBlock": { "auth_ref": [ "r40", "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for condensed financial statements.", "label": "Condensed Financial Statements [Text Block]", "terseLabel": "UNAUDITED INTERIM FINANCIAL STATEMENTS" } } }, "localname": "CondensedFinancialStatementsTextBlock", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/UnauditedInterimFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Other account payables and accrued expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r228", "r259" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r171", "r247", "r248", "r249", "r253", "r260" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r37", "r46", "r60", "r84", "r86", "r88", "r91", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r123", "r127", "r139", "r151", "r191", "r228", "r239", "r251", "r252", "r255" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r43", "r48", "r60", "r91", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r123", "r127", "r139", "r228", "r251", "r252", "r255" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r9", "r45", "r223" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r9", "r28", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r28" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r247", "r248", "r253", "r258", "r260" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails", "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherValueOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Value, Outstanding", "terseLabel": "Amount received (in Dollars)" } } }, "localname": "CommonStockOtherValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17", "r179" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "netLabel": "Common stock share issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.raphaelpharmaceutical.com/role/GeneralDetails", "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r17", "r179", "r197", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.raphaelpharmaceutical.com/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r152", "r228" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value:Authorized: 21,020,560 shares at June 30, 2023 and December 31, 2022;Issued and outstanding: 16,368,168 and 15,624,040 at June 30, 2023 and December 31, 2022, respectively;" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r10", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r3", "r13" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r54", "r67", "r68", "r69", "r70", "r71", "r75", "r77", "r79", "r80", "r81", "r82", "r137", "r138", "r149", "r158", "r224" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r54", "r67", "r68", "r69", "r70", "r71", "r77", "r79", "r80", "r81", "r82", "r137", "r138", "r149", "r158", "r224" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r4", "r41", "r51", "r52", "r53", "r62", "r63", "r64", "r66", "r72", "r74", "r83", "r92", "r93", "r115", "r116", "r117", "r118", "r120", "r121", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r160", "r161", "r162", "r171", "r216" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails", "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r5" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Agreed amount (in Dollars)" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Investment amount (in Dollars)" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares issued" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r33", "r148" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Fixed assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r26", "r201" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r2" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "terseLabel": "Account payables and related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r245" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r38", "r155", "r228", "r246", "r250", "r254" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r44", "r60", "r91", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r124", "r127", "r128", "r139", "r228", "r251", "r255", "r256" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r28", "r29", "r30" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r30", "r39", "r42", "r49", "r50", "r53", "r60", "r65", "r67", "r68", "r69", "r70", "r73", "r74", "r78", "r84", "r85", "r87", "r89", "r91", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r138", "r139", "r157", "r199", "r214", "r215", "r225", "r237", "r251" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTotalLabel": "Net loss", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement", "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Total financial expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r6" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Payable to related party" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r84", "r85", "r87", "r89", "r225" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedTotalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r15", "r36", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "GENERAL" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r47", "r228" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r25", "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Service provided (in Dollars)" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r1" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r42", "r49", "r50", "r55", "r60", "r65", "r73", "r74", "r84", "r85", "r87", "r89", "r91", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r122", "r125", "r126", "r138", "r139", "r150", "r156", "r170", "r199", "r214", "r215", "r225", "r226", "r227", "r238", "r244", "r251" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r14", "r119", "r257" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r35", "r154", "r163", "r164", "r169", "r180", "r228" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r41", "r62", "r63", "r64", "r66", "r72", "r74", "r92", "r93", "r116", "r117", "r118", "r120", "r121", "r129", "r131", "r132", "r134", "r136", "r160", "r162", "r171", "r260" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsUnappropriated": { "auth_ref": [ "r19", "r59", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.", "label": "Retained Earnings, Unappropriated", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsUnappropriated", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/GeneralDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r2" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based payment in exchange for services" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Share exchange common stock" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r31", "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r4", "r8", "r41", "r51", "r52", "r53", "r62", "r63", "r64", "r66", "r72", "r74", "r83", "r92", "r93", "r115", "r116", "r117", "r118", "r120", "r121", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r160", "r161", "r162", "r171", "r216" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails", "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r62", "r63", "r64", "r83", "r147", "r167", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r232" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r62", "r63", "r64", "r83", "r147", "r167", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r232" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of common stock in exchange for services (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r4", "r16", "r17", "r35", "r168", "r216", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock and warrants (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock in exchange for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r4", "r16", "r17", "r35", "r171", "r216", "r221", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock and warrants" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r32", "r181", "r197", "r217", "r218", "r228", "r239", "r246", "r250", "r254", "r260" ], "calculation": { "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet", "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r34", "r59", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r135", "r219", "r220", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransferToInvestments": { "auth_ref": [ "r10", "r11", "r12" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of investments transferred to the entity's investments in noncash transactions.", "label": "Transfer to Investments", "terseLabel": "Investor transferred (in Dollars)" } } }, "localname": "TransferToInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r76", "r81" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares used in computing diluted net loss per share (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r75", "r81" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares of common stock used in computing basic net loss per share (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.raphaelpharmaceutical.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(ii))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(7)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r241": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r242": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r243": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r31": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>32 <FILENAME>0001213900-23-065005-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 0001213900-23-065005-xbrl.zip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end </TEXT> </DOCUMENT> </SEC-DOCUMENT>